 
  A Phase I  Randomized, Double -Blind, Placebo -Controlled Study of a Multi -
Antigen DNA Vaccine  Prime  Delivered by In Vivo Electroporation , rVSV Boost er 
Vaccine  in HIV -Infected Patients Who Began Antiretroviral Therapy During 
Acute/Early Infection  
 
 
 
 
 
 
 
Version Number:    6.0 
 
NIAID Protocol Number:   13-I-0141  
 
Date:      August  14, 2015 
 
Principal Investigator:   Michael C. Sneller, MD  
 
Pharmaceutical Support  
Provided by:     Profectus Biosciences, Inc.  
     Ichor Medical Systems  
 
Investigational New  
Drug (IND) #:     15459  
 
Medical Monitor:    Marc Teitelbaum, MD  
 
 
 
 
 
 
 
 
Sponsored by:  
Office of Clinical Research Policy and Regulatory Operations (OCRPRO)  
Division of Clinical Research  (DCR) , Office of the Director  
National Institute of Allergy and Infectious Diseases (NIAID)  
NIH 
 
 Study Staff Roster  
 
Principal Investigator:   Michael C. Sneller, MD  
     Laboratory of Immunoregulation (LIR)/NIAID  
     Phone: 301.496.0491  
     E-mail: msneller@niaid.nih.gov  
 
Associate Investigators :  Tae-Wook Chun, PhD  
     LIR/NIAID  
     Phone: 301.496.0890  
     E-mail: twchun@niaid.nih.gov  
 
Richard  Davey, MD  
LIR/NIAID  
Phone: 301.49 6.8029  
E-mail: rdavey@niaid.nih.gov  
 
Michael A. Egan, PhD  
Profectus Biosciences, Inc.  
777 Saw Mill River Road  
Tarrytown, NY 10591  
Phone: 443 .743.1113  
E-mail: eganm@profectusbiosciences.com  
 
John H. Eldridge, PhD  
Profectus Biosciences , Inc.   
777 Saw Mill River Road  
Tarrytown, NY 10591  
Phone: 443.743.1111  
E-mail: eldridge@profectusbiosciences.com  
 
Research Contact/Study  
Coordinator(s):    Kathleen Gittens   
     Clinical Center /Critical Care Medicine Department  
     Phone: 301 .435.8003  
     E-mail: kathleen.gittens@nih.gov  
 
Statistician:  Michael Proschan, PhD  
Biostatistics Research Branch/DCR  
Phone: 301.451.5129  
E-mail: proscham@niaid.nih.gov  
 
Sponsor Medical Monitor:   Marc Teitelbaum, MD [C]  
 HIV-MAG pDNA vaccine  version 6.0 
 August  14, 2015            
Page 3 of 72 Leidos Biomedical Research, Inc.  
Frederick National Laboratory  
Phone (301) 228 -4707  
Fax (301) 846 -6224  
E-mail: RCHSPSafety@ mail.NIH. gov 
  
 HIV-MAG pDNA vaccine  version 6.0 
 August  14, 2015            
Page 4 of 72 Table of Contents  
Study Staff Roster  ................................ ................................ ................................ ...........  2 
Protocol Summary  ................................ ................................ ................................ ...........  9 
1 Background Information and Scientific Rationale  ................................ ...................  13 
1.1 Background Information  ................................ ................................ ..................  13 
1.1.1 Description of the Study Agents  ................................ ...............................  15 
1.1.2  Summary of Previous Pre -Clinical Studies  ................................ ...............  18 
1.1.3  Summary of Relevant Clinical Studies ................................ ......................  23 
1.2 Rationale  ................................ ................................ ................................ .........  31 
2 Study Objective  ................................ ................................ ................................ ..... 32 
2.1 Primary Objective  ................................ ................................ ............................  32 
2.2 Secondary Objectives  ................................ ................................ .....................  32 
2.3 Exploratory Objectives  ................................ ................................ ....................  32 
3 Study Design  ................................ ................................ ................................ .........  32 
3.1 Description of the Study Design  ................................ ................................ ...... 32 
3.2 Study Endpoints  ................................ ................................ ..............................  33 
3.2.1  Primary Endpoint  ................................ ................................ .....................  33 
3.2.2  Secondary Endpoint  ................................ ................................ .................  34 
3.2.3  Exploratory Endpoints  ................................ ................................ ..............  34 
4 Study Population  ................................ ................................ ................................ ... 34 
4.1 Rationale for Subject Selection  ................................ ................................ ....... 34 
4.2 Recruitment Plan ................................ ................................ .............................  34 
4.3 Subject Inclusion Criteria  ................................ ................................ .................  34 
4.4 Subject Exclusion Criteria  ................................ ................................ ...............  35 
5 Justification for Exclusion of Women and Children (Special Populations)  ..............  37 
6 Study Agent/Interven tions  ................................ ................................ ......................  37 
6.1 Disposition and Dispensation  ................................ ................................ ..........  37 
6.1.1  Formulation, Packaging and Labeling  ................................ ......................  37 
6.2 Study Agent Storage and Stability  ................................ ................................ ... 37 
6.3 Preparation, Administration, and Dosage of Study Agent /Intervention(s)  ........  38 
6.4 Concomitant Medications and Procedures  ................................ ......................  40 
6.5 Prohibited Prescription Medications and Procedures  ................................ ...... 41 
7 Study Schedule  ................................ ................................ ................................ ..... 41 
7.1 Screening  ................................ ................................ ................................ ........  41 
7.2 Enrollment/Baseline  ................................ ................................ ........................  41 
7.3 Randomization  ................................ ................................ ................................  42 
7.4 Vaccination Phase  ................................ ................................ ..........................  42 
7.5 Post-Vaccination ATI Phase  ................................ ................................ ............  43 
7.6 Post-Vaccination, Post -ATI Phase  ................................ ................................ .. 44 
8 Study Procedures/Evaluations  ................................ ................................ ...............  45 
8.1 Clinical Evaluations  ................................ ................................ .........................  45 
8.2 Research Evaluations  ................................ ................................ .....................  46 
9 Potential Risks and Benefits  ................................ ................................ ..................  47 
9.1 Potential Risks  ................................ ................................ ................................  47 
Leukapheresis  ................................ ................................ ................................ ....... 50 
9.2 Potential Benefits  ................................ ................................ ............................  50 
10 Research Use of Stored Human Samples, Specimens or Data ..........................  50 
11 Remuneration Plan for Subjects  ................................ ................................ ........  51 
12 Assessment of Safety  ................................ ................................ ........................  51 
12.1 Documenting, Recording, and Reporting Adverse Events  ...........................  51 
 HIV-MAG pDNA vaccine  version 6.0 
 August  14, 2015            
Page 5 of 72 12.2 Definitions  ................................ ................................ ................................ .... 51 
12.3 Investigator Assessment of Adverse Events  ................................ ................  53 
12.3.1  Severity  ................................ ................................ ................................  54 
12.3.2  Causality  ................................ ................................ ..............................  54 
12.4 Investigator Reporting Responsibilities to the Sponsor  ................................  55 
12.4.1  Adverse Events  ................................ ................................ ....................  55 
12.4.2  Serious Adverse Events  ................................ ................................ ....... 55 
12.4.3  Unanticipated Problems  ................................ ................................ ........  56 
12.4.4  Protocol Specified Events  ................................ ................................ ..... 56 
12.4.5  Pregnancy  ................................ ................................ ............................  56 
12.5 Investigator Reporting Responsibilities to the NIAID IRB  .............................  56 
12.5.1  Expedited Reporting to the NIAID IRB  ................................ ..................  56 
12.5.2  Annual Reporting to the NIAID IRB  ................................ .......................  57 
12.6 Follow -up of Adverse Events and Serious Adverse Events  ..........................  57 
12.7 Sponsor’s Reporting Responsibilities  ................................ ...........................  57 
12.8 Halting Criteria For The Protocol ................................ ................................ .. 58 
12.8.1  Reporting of Study Halting  ................................ ................................ .... 58 
12.8.2  Resumption of a Halted Study  ................................ ..............................  58 
12.9 Pausing Criteria for a Subject or Group  ................................ .......................  58 
12.9.1  Reporting of Pausing for a Subject or Group  ................................ ........  59 
12.9.2  Resumption of Pausing for a Subject or Group  ................................ ..... 59 
12.10  Withdrawal Criteria for an Individual Subject  ................................ ................  59 
12.11  Replacement for Withdrawn Subjects  ................................ ..........................  60 
12.12  Safety Oversight  ................................ ................................ ..........................  60 
12.12.1  Safety Review and Communications Plan  ................................ ............  60 
12.12.2  Sponsor Medical Monitor  ................................ ................................ ...... 61 
12.12.3  Data and Safety Monitoring Board  ................................ ........................  61 
13 Clinical Monitoring Structure  ................................ ................................ ..............  61 
13.1 Site Monitoring Plan ................................ ................................ .....................  61 
13.1.1  Study Blinding and Unblinding  ................................ ..............................  62 
14 Compliance With NIH Guidelines for Research Involving Products Containing 
Recombinant DNA  ................................ ................................ ................................ ........  62 
15 Statistical Considerations  ................................ ................................ ...................  63 
15.1 Study Hypotheses  ................................ ................................ .......................  63 
15.2 Sample Size Justification  ................................ ................................ .............  63 
16 Ethics/Protection of Human Subjects  ................................ ................................ . 64 
16.1 Informed Consent Process  ................................ ................................ ..........  64 
16.2 Subject Confidentiality  ................................ ................................ .................  64 
17 Data Handling and Record Keeping  ................................ ................................ ... 64 
17.1 Data Management Responsibilities  ................................ ..............................  65 
17.2 Data Capture Methods  ................................ ................................ .................  65 
17.3 Types of Data  ................................ ................................ ..............................  65 
17.4 Source documents and Access to Source Data/Documents  ........................  65 
17.5 Record Retention  ................................ ................................ .........................  65 
Appendix A: Scientific References  ................................ ................................ .................  67 
Appendix B: Schedule of Evaluations  ................................ ................................ ............  70 
Appendix C: AEs of Special Interest  ................................ ................................ ..............  71 
Appendix D: Vaccine Diary Card  ................................ ................................ ...................  72 
 
 
 HIV-MAG pDNA vaccine  version 6.0 
 August  14, 2015            
Page 6 of 72  
List of Tables  
Table 1: Previous clinical use of the HIV -MAG pDNA vaccine,  IL -12 pDNA, TDS device, 
and the rVSV HIV gag vaccine  ................................ ................................ .......................  24 
Table 2: Schedule of reactogenicity assessments  ................................ ..........................  46 
Table 3: Probability of observing at least 1 vaccine recipient out of 15 with an AE that has 
probability P of occurring in a given participant  ................................ ...............................  63 
 
List of Figures  
Figure 1:  Map of HIV -1gag/pol pDNA (WLV -151M) and HIV -1 nef/tat/vif , env pDNA (WLV -
255M)  ................................ ................................ ................................ .............................  16 
Figure 2: Map of IL -12 pDNA  ................................ ................................ ..........................  16 
Figure 3 : The Ichor TDS device  ................................ ................................ ......................  17 
Figure 4 : Genomic organization of wild type VSV and the vaccine vector, 
rVSV INN4CT1gag1  ................................ ................................ ................................ .........  18 
Figure 5: SIV -specific IFN -γ ELISpot responses in immunized SIV -infected rhesus 
macaques  ................................ ................................ ................................ ......................  22 
Figure 6: SIV gag-specific epitope breadth in immunized SIV -infected rhesus macaques 23 
Figure 7: HIV -specific CD4+ intracellular cytokine staining responses from the HVTN  080 
study  ................................ ................................ ................................ ..............................  27 
Figure 8: HIV -specific CD8+ intracellular cytokine staining responses from the HVTN -080 
study  ................................ ................................ ................................ ..............................  28 
Figure 9: HVTN 090: Maximum local reactogenicity by treatment group .........................  30 
Figure 10: HVTN 090: Maximum systemic reactogenicity by treatment group  ................  31 
  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 7 of 72 List of Abbreviations  
 
ALT   Alanine Aminotransferase  
AE   Adverse Event/Adverse Experience  
AR   Adverse Reaction  
ART   Antiretroviral Therapy  
AST   Aspartate Aminotransferase  
ATI   Analytical Treatment Interruption  
BGH    Bovine Growth Hormone  
bp   Base Pair  
cART    Combination Antiretroviral  Therapy  
CBC    Complete Blood Count  
CFR   Code of Federal Regulations  
CPK   Creatine Phosphokinase  
CRIMSON  Clinical Research Information Management System of the NIAID  
CSO  Clinical Safety Office  
CT Cytoplasmic Tail  
DAIDS  Division of AIDS  
DCR    Division of Clinical Research  
DSMB    Data and Safety Monitoring Board  
ECG    Electrocardiogram  
EDTA    Ethylenediaminetetraacetic Acid  
EIA   Enzyme Immunoassay  
ELISpot   Enzyme -Linked Immunos orbent  Spot Assay  
EP   Electroporation  
FDA   Food and Drug Administration  
GCP   Good Clinical Practice  
HBsAg   Hepatitis B Surface Antigen  
HCMV    Human Cytomegalovirus  
HCV    Hepatitis C Virus  
HIV-1   Human Immunodeficiency Virus Type 1  
HIV-MAG  pDNA  HIV-1 Multiantigen Plasmid DNA  
ICH   International Conference on Harmonization  
ICS   Intracellular Cytokine Staining  
IFN   Interferon  
IL   Interleukin  
IL-12 pDNA   Interleukin 12 Plasmid DNA  
IM   Intramuscular  
IND   Investigational New Drug  
IRB   Institutional Review Board  
NIAID    National Institute of Allergy and Infectious Diseases  
NIH   National Institutes of Health  
NNRTIs   Non-Nucleoside Reverse Transcriptase Inhibitors  
OCRPRO   Office of Clinical Research Policy and Regulatory Operations  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 8 of 72 OHRP    Office for Human Research Protec tions  
PBMCs   Peripheral Blood Mononuclear Cells  
PCR    Polymerase Chain Reaction  
pDNA    Plasmid DNA  
Pfu   Plaque -Forming Units  
PolyA    Polyadenylation  
PT Prothrombin Time  
PTT Partial Thromboplastin T ime 
rVSV  Recombinant Vesicular Stomati tis Virus   
rVSV HIV gag Recombinant Vesicular Stoma titis Virus Vector Containing the HIV -
1 Gag Gene  
rVSV IN  Recombinant Indiana Serotype Vesicular Stomatitis Virus  
SAE   Serious Adverse Event/Serious Adverse Experience  
SAR   Suspected Adverse Reaction  
SCMV    Simian Cytomegalovirus  
SIV   Simian Immunodeficiency Virus  
SLE   Systemi c Lupus Erythematosis   
SRCP    Safety Review and Communication Plan  
SUSAR   Serious And Unexpected Suspected Adverse Reaction  
SV   Simian Virus  
TDS   TriGrid® Delivery System  
ULN   Upper Limit of Normal  
UP   Unanticipated Problem  
VPA   Valproic Acid  
VSV   Vesicular Stomatitis Virus  
VSV IN    Indiana Serotype  Vesicular Stomatitis Virus  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 9 of 72 Protocol Summary  
 
Full Title:  A Phase I  randomized, double -blind, placebo -controlled 
study of a multi -antigen DNA vaccine  prime  delivered by in 
vivo electroporation , rVSV boost er vaccine  in HIV -infected 
patients who began antiretroviral therapy during acute/early 
infection.  
Short Title:    HIV-MAG  pDNA prime, rVSV boost . 
Clinical Phase:  Phase I. 
IND Sponsor:    OCRPRO  
Conducted by:   LIR/NIAID.  
Principal Investigator:  Michael C. Sneller, MD.  
Sample Size:  n=30  subjects with human immunodeficiency virus type 1 
(HIV-1). 
Accrual Ceiling:  n=50.  
Study Population:  Adults  (18-65 years of age ) on combination antiretroviral 
therapy (cART)  who started therapy during early or acute  
HIV-1 infection .  
Accrual Period:  18 months . 
Study Design:  This is a randomized,  2-arm (1:1), double -blind, placebo -
controlled study ev aluating the safety and efficacy of an 
HIV-1 multi antigen plasmid DNA (HIV-MAG  pDNA ) vaccine 
prime in combination with an interleukin 12 plasmid DNA 
(IL-12 pDNA) adjuvant , delivered by intramuscular (IM) 
electroporation (EP),  and a recombinant vesicular stomati tis 
virus vector containing the HIV-1 gag gene (rVSV HIV gag) 
booster  vaccine  delivered by  conventional  IM injection . 
Study Duration:  Start Date: August 2013 . 
 End Date : November 2016 . 
Study Agent s/  
Intervention Description:  HIV-MAG pDNA vaccine  prime (Profectus Biosciences, 
Inc.; Tarrytown, NY) will be administered  at a dose of 3000 
µg (1500 µg  of the HIV-1 gag/pol  plasmid and 1500 µg  of 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 10 of 72 the HIV-1 net/tat/vif , env plasmid ) at week 0, 4, 12, and 36 . 
Each construct of HIV -MAG pDNA vaccine (1500 µg each) 
will be mixed  and combined  with 1000 µg  of the IL -12 pDNA 
adjuvant . The resulting mixture  will be divided and 
administered as 2 IM injections, 1 into each deltoid, with EP 
using the Ichor Medical Systems (San Diego, CA) TriGrid® 
Delivery System (TDS) device.  
 IL-12 pDNA adjuvant  (GENEVAX®; Profectus Biosciences, 
Inc.; Tarrytown, NY) will be mixed with the HIV MAG pDNA 
vaccine , as noted  above, and administered at a dose of 
1000 µg (500 µg in each IM injection ) at week 0 , 4, 12, an d 
36. 
 rVSV HIV gag booster vaccine  (Profectus Biosciences, 
Inc.; Tarrytown, NY) will be administered as 2  conventional  
IM injections  (1 mL each) , 1 into each deltoid , for a total 
dose of 1x107 plaque -forming units (pfu) at week 24 and 48.  
Primary Objective:  To evaluate safety and  tolerability of the study  vaccine s in 
subjects who began cART during acute or early HIV -1 
infection.  
  Secondary Objective s: To evaluate t he efficacy of the study vaccine s as 
determined by its effect on rebound viremia following 
analytical  treatment interruption  (ATI) . 
Exploratory Objective s: 1. To assess the effect of the study vaccine s on the rate of 
decay of the HIV -infected, CD4+  T-cell reservoir . 
 2. To determine the i mmun ogenicity of  the study vaccine s. 
Primary Endpoint:  The rate of occurrence of grade 3 or higher AEs , including 
serious adverse events (SAEs) that per standard criteria 
(see safety section) are:  
 At least possibly related to the test article, and 
 Definitely NOT related to a factor other than the test 
article . 
Secondary Endpoint:        The difference in HIV -1 viral load  at the end of the  ATI 
between the vaccine and placebo groups . 
Exploratory Endpoint s:  1. The frequency and rate of decay of the infectious HIV 
reservoir between the vaccine and placebo  groups .  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 11 of 72  2. Change from baseline ( mean of entry and pre -entry) to post- 
vaccination in the number of interferon ( IFN)-γ/ interleukin ( IL)-2-
generating  CD8+ an d CD4+ T -cells/million peripheral blood 
mononuclear cells ( PBMCs ); in response to gag, pol, env, nef, tat 
and vif, as measured by intracellular cytokine staining ( ICS). 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 12 of 72 Précis  
 
The advent of  combination  antiretroviral therapy ( cART) has dramatically improved the 
clinical outcome in human immunodeficiency virus ( HIV)-infected individuals through 
sustained reduction in viral replication. However, it has become clear that cART  alone 
cannot eradicate HIV in infected individuals, likely in part due to the persistence of viral 
reservoirs in peripheral blood and various tissue compartments. Consequently, a major 
thrust of HIV research over the past several years has been to develop  therapeutic 
strategies that can  eliminat e persistent viral reservoirs and  boost host immunity to control  
viral replication upon discontinuation of cART. Therapeutic HIV vaccination is one 
approach that could potentially  achieve  these goals through  vaccine -induced  
improvement in  HIV-specific immune responses and/or by direct reactivation of HIV -
specific CD4+ memory T cells  that harbor latent HIV. A n effective therapeutic vaccine 
could augment immunologic control of HIV infection and potentially obviate the need for 
chronic cART .  
 
The current study is a n exploratory  randomized, 2 -arm (1:1), double -blind, placebo -
controlled trial evaluating the safety and efficacy of an HIV -1 multiantigen plasmid DNA 
(HIV-MAG pDNA) vaccine prime in combination with an interleukin -12 plasmid DNA (IL -
12 pDNA) adjuvant  delivered by in vivo electroporation  followed by a recombinant 
vesicular stomatitis virus vector containing the HIV -1 gag gene (rVSV HIV gag) booster 
vaccine in subjects on cART who started therapy during acute or early HIV infection.  
 
Subjects will be randomized to receive placebo or t he HIV -MAG pDNA (3000 µg) vaccine 
prime and IL -12 pDNA adjuvant (1000 µg) at week 0, 4, 12, and 36 , and the rVSV HIV 
gag boost er vaccine  (1x107 plaque -forming units)  at week 24 and 48. The HIV -MAG 
pDNA vaccine prime and IL -12 pDNA adjuvant will be administered as 2 IM injections, 1 
into each deltoid, with electroporation  using the Ichor TDS device, while the rVSV  HIV 
gag booster vaccine will be administere d as 2  conventional  IM injections , 1 into each 
deltoid. After the week 56  visit, all subjects will undergo an analytical treatment 
interruption to determine if the vaccination strategy results in an improved immune control 
of viral replication, as eviden ced by a  blunted or absent  rebound  in HIV plasma viremia . 
All subjects will be followed through week 96 for safety and efficacy  parameters .  
 
The study population includes  HIV-infected adults  who began cART during acute or early 
infection . Subjects must be receiving an effective cART regimen , with a CD4 cell count of 
>450 cells/mm3 at screening , and they must have documented viral suppression below 
the limit of detection for >1 year. The rationale for testin g the study vaccine regimen in 
this subject  population is because  these individuals  may have a relatively preserved 
immune function , which  could be augmented by therapeutic vaccination.  
 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 13 of 72 1 Background Information and Scientific Rationale  
1.1 Background Information  
Prolonged suppression of plasma viremi a is now achievable in the majority of HIV -
infected individuals receiving cART.1 However, complete eradication of HIV has not 
been possible using cART alone, likely due to the persistence of various viral 
reservoirs.2-4 Previous studies have demonstrated that HIV persists in latently 
infected, CD4+ T cells in the peripheral blood of virtually all infected individuals 
receiving clinically effective doses of cART .5-7 In addition, evidence from a number 
of recent studies has suggested that low levels of HIV replication may persist in 
such individuals in the absence of detectable viremia.8-10 Given that plasma viremia 
rapidly rebounds in virtually all HIV -infected individuals upon cessation of cART, 
regardless of the duration and timing of therapy,11,12 therapeutic strategies aimed at 
destroying persistently infected cells are needed to achieve complete eradication of 
HIV.13 
 
Nearly a decade ago, several clinical studies tested the feasibility of purging latent 
HIV reservoirs in infected individuals receiving cART, with the use of non -specific 
immune -activating agents, such as IL -214 and an anti -CD3 antibody.15 In a non -
randomized study, subjects who received cART plus repeated cycles of intermittent 
IL-2 exhibited a marked diminution of the pool of latently infected, resting CD4+ T 
cells, compared with those recei ving cART alone;14 nonetheless, rapid rebound of 
plasma viremia was observed following interruption of cART.12 More recently, 
valproic acid (VPA), a histone deacetylase inhibitor, was tested in humans as a 
potential virus -“purging” agent and was shown in o ne study to diminish the size of 
the latent viral reservoir in infected individuals receiving ART.16 However, 
subsequent studies demonstrated no appreciable reduction of the latent viral 
reservoir following treatment with VPA.17,18  
 
Other therapeutic strategies aimed at achieving eradication are under  investigation. 
These include genetic manipulation of CD4+ T cells (deletion of one of the HIV co -
receptors chemokine receptor type 5)19,20 and stem -cell transplantation.21 Although 
it appears that eradication of HIV was achieved in one individual who underwent 
multiple rounds of chemotherapy and stem -cell transplantation,21 it is unlikely that 
this approach can be safel y applied to a substantial proportion of the HIV-infected 
population. Considering the difficulties encountered with these modalities, a more 
realistic approach is needed to explore the therapeutic strategies that harness host 
immunity to control HIV replic ation in infected individuals in the absence of cART (a 
“functional” cure).4 One such strategy is therapeutic vaccination.  
 
The goal of therapeutic vaccination is to induce or augment virus -specific immune 
responses using a planned exposure to HIV antigen s. A successful therapeutic 
vaccination regimen would sufficiently augment the immune response to HIV such 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 14 of 72 that control of viral replication could be achieved in the absence of cART, thus, 
mimicking the unique immune response of a small portion of HIV -infected 
individuals who are able to control viral replication in the absence of treatment 
(variably termed elite controllers or long -term non -progressors). Early attempts at 
therapeutic vaccination in HIV -1-infected individuals during the pre -cART era were 
largely unsuccessful; however, these results were not unexpected. The 
introduction of a small amount of exogenous antigen in the form of a therapeutic 
vaccine is unlikely to have a significant immunostimulatory effect in chronically 
infected individuals with  uncontrolled viral replication and ongoing CD4 cell death.  
 
More recent pre -clinical and clinical studies, performed in the cART era, have 
shown improvement of virus -specific immune responses after therapeutic 
vaccination. The induction of broad T -cell responses was observed in a macaque 
simian immunodeficiency virus ( SIV) model using  DNA vaccine during suppressive 
cART.22 Vaccination reduced virus burden in the gut and blood , compared with 
unvaccinated controls and provided durable protection from viral rebound and 
disease progression following ART interruption. In the ACTG study 5197, 
vaccination of subjects receiving suppressive cART with an Ad5 HIV gag vector 
induced moderate increases i n HIV -specific T -cell responses.23 Vaccinated 
subjects showed a modest decrease in their viral load set point at the end of the 
ATI, compared with unvaccinated controls ; however, the decrease did not reach 
the pre -specified level of s ignificance ( P <0.025). In a recently published 
randomized controlled study by Garcia  et al,24 subjects receiving the active 
dendritic cell vaccine  (autologous dendritic cells pulsed with autologous heat 
inactivated virus ) had  a significant decrease in viral set point following ATI  
compared to controls .  
 
The studies presented above suggest that therapeutic vaccination could become a 
promising immune -based modality for the treatment of HIV -1 infection, if more 
immunogenic vaccinat ion strategies can be developed. Our trial will utilize a pDNA 
prime/live virus vector boost vaccination strategy that has been shown to elicit a 
strong HIV -specific cellular immune response  in pre -clinical animal models . This 
vaccination regimen has addit ional features designed to maximize immunogenicity.  
For example , the HIV -MAG  pDNA  vaccine prime -IL-12 pDNA adjuvant  will be 
administered to study participants  via an in vivo  EP delivery system. EP is a 
technology in which a transient electric field is applied to enhance the cellular 
uptake of large molecules, such as DNA, and it has been shown to provide an 
efficient method of delivering DNA into the cell.25 Preclinical stud ies in nonhuman 
primates provide compelling evidence that in vivo  EP enhances the potency of the 
HIV-MAG  pDNA /IL-12 pDNA vaccine  (see Section 1.1.2 ). In addition, clinical 
studies indicate that EP delivery of pDNA vaccines is safe and well tolerated .26 
Second ly, the vaccine regimen will utilize an IL -12 pDNA adjuvant that, when 
administered by in vivo EP, is designed to enhance the immunogenicity of the 
pDNA vaccine.  Third ly, the booster component of the vaccine utilizes a 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 15 of 72 recombinant vesicular stomati tis virus (rVSV )-vector encoding HIV gag. Wild -type 
vesicular stomatitis virus (VSV) rarely causes infections in humans; thus, the use of 
an rVSV vector will minimize any interference of pre -existing immune responses in 
study subjects.  
1.1.1  Description of the Study Agent s 
HIV-MAG pDNA vaccine  prime  
The HIV -MAG pDNA vaccine consists of 2 DNA expression vectors ( HIV-1 
gag/pol  [WLV -151M ] and HIV-1 nef/tat/vif , env [WLV -255M ]) encoding 
multiple HIV -1 clade B antigens ( Figure 1). WLV -151M is a 7,487 -base pair  
(bp) plasmid expressing an HIV-1 clade B ( HIV-1HXb2) Gag/Pol fusion protein 
control led by  the human cytomegalovirus  (HCMV) immediate early promoter 
and the bovine growth hormone (BGH) polyadenylation (polyA) signal. WLV -
255M is a dual -promoter plasmid (8,750 bp) expressing an HIV -1 clade B 
primary isolate (HIV -16101) Env gp160 controlled by the simian 
cytomegalovirus (SCMV) promoter and the BGH polyA, and an HIV -1 clade B 
(HIV-1NL43) Nef/Tat/Vif fusion protein utilizing the HCMV promoter and the 
simian virus (SV)40 polyA tail.  
 
IL-12 pDNA adjuvant  
IL-12 pDNA adjuvant is a dual -promoter expression plasmid ( Figure 2) that is 
6,259 bp long and consist s of 2 genes encoding the human IL -12 proteins 
p35 and p40. Each cistron contains one of the two IL -12 subunits, p35 or p40, 
and each subunit is control led by  independent regulatory elements. The p35 
subunit is controlled by the HCMV promoter/  enhancer and the SV40 poly A 
signal. The p40 subunit is regulated by the SCMV promoter and the BGH 
polyA signal.  
 
 
 
 
 
 
 
 
 
 
 
 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 16 of 72  
Figure 1: Map of HIV -1gag/pol pDNA (WLV -151M) and HIV -1 nef/tat/vif , env pDNA 
(WLV -255M)  
 
WLV151M                                                                         WLV255M  
 
 
 
 
 
 
 
 
Figure 2: Map of IL -12 pDNA  
 
 
 
WLV151M
(7487 bp)
H C M V pr om ot e rkanam yc i n
O r i  s e que nc eBG H  pol y A
H I V  gag/ polWLV255M.gcs
(8750 bp)SV40pol yAHCM V
SCM V
Ka na m yc i n
Or i  s e que nc eHI V ne f / t a t / vi f
H I V e nv 6101 ( gp160)

HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 17 of 72  
Ichor TriGrid delivery system  device  
The Ichor TDS device is designed for IM administration of DNA. Specifically, 
the device is designed to propagate EP inducing transient electrical fields at 
the site of administration in the presence of DNA , thus, enhancing  its cellular 
uptake. The TDS device has been shown to be an efficient met hod for 
delivering DNA into cell ,25 and p reclinical studies have suggested that in vivo 
EP enhances the potency of a DNA vaccine.27,28 
 
The TDS device consists of 3 components depicted in Figure 3 . They include 
a single -use application cartridge, an integrated applicator, and a pulse 
stimulator. The current configuration of the device is designed for the 
administration of investigational agents in the context of early phase human 
clinical studies. To prov ide the degree of flexibility necessary to support novel 
product candidates entering the clinical -phase testing, the TDS device has 
been designed to interface with a standard, “off -the-shelf” syringe and can 
accommodate injection volumes of 0.5 mL to  1.2 m L.   
 
Figure 3: The Ichor TDS device  
 
 
rVSV HIV gag booster vaccine  
The rVSV HIV gag booster vaccine preparation contains an attenuated, 
replication -competent form of the lab-adapted recombinant Indiana serotype 
vesicular stomatitis virus (rVSV IN) that expresses the HIV -1 clade  B (strain 
HXB2) Gag protein. The vaccine vector was attenuated by translocation of 
the virus N gene from the first position (N1) in the genome to the fourth  
position (N4) and truncation of the virus G protein cytoplasmic tail (CT) from 
29 amino acids to 1 amino acid (CT1). The HIV -1 gag gene was inserted at 

HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 18 of 72 
the first position ( gag1 ) in the rVSV genome adjacent to the virus messenger 
RNA transcription promoter  to maximize Gag protein expression. The vaccine 
vector has been named to reflect the major attenuating mutations, the 
position of the gag gene , and the vector serotype (Fig ure 4 ). 
 
Figure 4: Genomic organization of wild type VSV a nd the vaccine vector, 
rVSV INN4CT1gag1  
 
 
 
   
 
 
 
WT=wild type; rVSV IN=recombinant Indiana serotype vesicular stomatitis virus.  
Numbering (e.g. N4, gag1) denotes the relative position s of genes within the viral genomes. The 
subscript IN (Indiana) describes the vector serotype. CT1 indicates that the length of the G 
protein cytoplasmic tail  is a single amino acid.  
 
1.1.2  Summary of Previous Pre -Clinical Studies  
An overview of pharmacokinetic, toxicological , and immunogenicity studies 
relevant to the clinical testing of the HIV -MAG pDNA vaccine alone , or in 
combination with human IL -12 pDNA adjuvant  (with or without TDS EP 
injector)  and the rVSV HIV gag booster vaccine , is presented below.  More 
detailed info rmation can be found in the investigator’s brochure documents . 
Biodistribution and persistence/integration study of the HIV -MAG pDNA 
in combination with the human IL-12 pDNA adjuvant delivered by  IM or 
IM EP injection  in rats 
A good laboratory practice study was carried out to characterize the systemic 
biodistribution and persistence/integration of the HIV -MAG pDNA vaccine in 
combination with the human IL -12 pDNA adjuvant  in rats . The formulated 
pDNA vaccine was administered bilaterally (tibialis anterior muscles) in  2 
groups of 22 rats each (11 rats/sex/group)  at a dose of 80 µg (32 µg HIV -1 
gag/pol , 32 µg HIV -1 nef/tat/vif, env , 16 µg IL-12 pDNA )  by conventional IM 
injection or IM EP delivery using the Ichor TDS device (for a total dose of 160 
µg per animal ). Additionally, a  group of 12 rats (6 rats/sex) was injected with 
saline using the TDS device.  Real-time quantitative polymerase chain 
reaction (PCR) was used to estimate the levels of the vaccine pDNA in tissue 
specim ens. The presence of the vaccine pDNA in the total DNA (genomic + 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 19 of 72 plasmid) isolated from the blood and various tissues was examined in this 
study at day 7 and day 60 post -vaccination. PCR analyses of tissue 
specimens obtained at day 7 showed that the distribution of the vaccine 
pDNA was largely confined to the tissues at the site of administration (muscle 
and skin)  following IM or IM EP delivery . On day 60,  the vaccine pDNA was 
detected in tissues at the site of administration in both the IM  and IM EP 
delivery  groups at levels of <7,000 copies/ µg. Plasmid levels decreased by 
approximately 1 to 2 orders of magnitude compared to the levels detected on 
day 7. These analyses indicate that IM and IM EP  delivery of the vaccine 
pDNA resulted in an initial up take of the plasmid , which was  localized to the 
injection site and then  decreased substantially over time. No significant 
differences were observed in the biodistribution or persistence of the  vaccine 
pDNA between the IM and IM EP delivery groups.     
Biodistribution and persistence study of the rVSV HIV gag vaccine 
delivered by  IM injection  in mice  
A virus  biodistribution stud y has been performed in mice to investigate the 
degree of virus replication and dissemination in a permissive host following 
IM vaccination .29 Mice were inoculated with the rVSV INN4CT9 gag1  vaccine at 
a dose of 108 pfu (10 x the anticipated  clinical dose) ; the rVSV INN4CT9 gag1  
is a closely related but more competent vector than rVSV INN4CT1 gag1 
vector . Vector replication and spread was monitored by assay ing the 
infectious virus and by virus - specific quantitative PCR performed  on tissue, 
blood , and organ samples collected at different time intervals post -injection  
(day 0 -2, 4, 8, and 10) . Results from  these studies showed  that all 
measurable virus replication was localized at the IM injection site  and in the 
major , draining poplilteal lymph node. Viral replication peaked at 1 to 2 days 
post-injection , and there was no evidence of viral gene express ion at 10 days 
post-injection . 
Repeat -dose toxicity study of the HIV-MAG pDNA vaccine with or 
without the human IL -12 pD NA adjuvant and the rVSV HIV gag booster  
vaccine delivered by IM  or IM EP injection in rabbits  
In a repeat -dose toxicology study , NZW rabbits  were administered  the HIV-
MAG pDNA vaccine as an IM injection at a dose of 4,000 µg with or without 
the human IL-12 pDNA adjuvant (1,000 µg) on day 1, 22, 43, 64, 85 , and 
106. A subgroup  of animals treated with the HIV-MAG pDNA vaccine and 
IL-12 pDNA  adjuvant also  received the rVSV HIV gag booster  vaccine on day 
64 and 85 by IM delivery.  Animals in all  groups exhibited minor  changes in 
body weight, food consumption, and clinical and anatomical pathology, 
generally with a complete or partial resolution of these changes by the end of 
the recovery period. Based on the se results,  it was concluded that the toxicity 
effects were localized or reflective of an inflammatory response targeted at 
the injection/ EP sites rather than being systemic  in nature .   
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 20 of 72 Toxic ology study  of the rVSV HIV gag vaccine delivered by IM injection 
in rabbits  
A good manufacturing practice  toxicology study was performed in 20 rabbits 
using the rVSV HIV gag vaccine.  No AEs were observed either at the 
injection site or systemically following the IM injection  of the rVSV HIV gag 
vaccine at a total dose of 108 pfu. Blood chemistry panels remained normal 
throughout the study and tissue/organ histopathology profiles were 
unremarkable in animals treated with the vaccine, compared with those in the  
placebo  group . 
 
Immunogenicity study of the HIV-MAG  pDNA vaccine  plus a rhesus IL-
12 pDNA adjuvant  with and without in vivo EP in rhesus macaques  
To determine the effect of EP on the immunogenicity of HIV -MAG  pDNA 
vaccination, a preclinical study was conducted in rhesus macaques  
immunized with an HIV -MAG pDNA  vaccine  (8500 µg)  plus a rhesus IL-12 
pDNA  adjuvant  (1500 µg) by conventional  IM injection or IM EP  delivery  
(1200 µg HIV MAG pDNA + 300 µg IL-12 pDNA ).30 Animals immunized by IM  
EP delivery exhibited  stronger cellular responses , compared with those 
immunized by conventional  IM injection . At 8 and 22 weeks after the final 
pDNA immunization , there was a 10 - and 45 -fold increase , respectively,  in 
HIV-specific IFN -γ responses , as measured by an enzyme -linked 
immunos orbent  spot ( ELISpot ) assay , in the IM EP delivery group , compared 
with the IM delivery group. Th e 10- and 45 -fold increase  translated into an 
apparent 50 - or 225 -fold increase in pDNA vaccine potency, respectively. 
Importantly, the IM EP delivery enhanced the immune response against the 
less immunogenic a ntigens ( nef-tat-vif), resulting in a more balanced immune 
response. In addition, antibody responses against the env antigen showed 
that the IM EP delivery led to an ~2.5-log increase in antibody titer , compared 
with the IM delivery  group.   
 
Immunogenicity  studies  of an rVSV SIV or HIV Gag p55 vaccine in 
rhesus macaques   
The first non-human primate  experiments to evaluate rVSV as a vector 
system for HIV infection  were conducted by Rose and colleagues at Yale. In 
a pioneering stud y, rhesus macaques (n=7) were immunized with a 
combination of 2 prototypic rVSV vectors expressing an HIV -1–89.6 env 
gp160/VSV -G fusion polypeptide and an SIV Gag p55 protein  or control 
(n=8) .31 In this study, all animals  in the combination vaccine group  remained 
disease -free after the challenge for >4 years. In contrast , all the macaques in 
the control group progressed to AIDS with in an average time of 8 months. 
The protection from AIDS in this study correlated with large differences in 
peak viral loads, low or undetectable viral loads at set  point, and the 
preservation of CD4+ T cells in the vaccine recipients relative to controls. 
This encouraging level of post -challenge vaccine efficacy suggested that 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 21 of 72 rVSV vectors expressing HIV genes might be an effect ive AIDS vaccine in 
humans.  
In a separate  unpublished study  conducted by  Profectus , groups of rhesus 
macaques were immunized at weeks 0 and 8 with a highly attenuated 
replication competent rVSV vaccine vector encoding the HIV-1 Gag p55 
protein (rVSV HIV gag) at a dose of 1x107 pfu or a much more virulent 
prototypic rVSV vector (rVSV -HIV gag5) vaccine at a dose of 1x107 pfu by 
conventional  IM injection ; the rVSV -HIV gag5 vaccine was previously shown 
by Rose and colleagues31 to protect macaques against simian -AIDS in a 
pathogenic SHIV (simian/human immunodeficiency virus) challenge model. 
The data demonstrate that the highly attenuated rVSV vector was as good as 
the more virulent vector in eliciting HIV gag-specific IFN -γ ELI Spot r esponses 
following vaccination  (rVSV INN4CT1gag1 vaccine Profectus Bioscience 
investigator’s brochure).  
 
Immunogenicity stud ies of an IL-12-enhanced SIV-MAG  pDNA vaccine 
plus an rVSV gag boost er vaccine  in rhesus macaques  
In a pre -clinical , immunogenicity study  conducted by Profectus , rhesus 
macaques  were infected with SIV and subsequently placed on cART until 
they reached  suppressive viremia. Macaques were then immunized with an 
IL-12-enhanced SIV -MAG  pDNA vaccine alone  or in combination with a 
heterologous rVSV booster  vaccine. Unimmunized control animals exhibited  
SIV-specific immune responses barely detectable by ELISpot and 
polyfunctional ICS assays. Animals  vaccinated with the IL -12-enhanced SIV-
MAG pDNA vaccine demo nstrated a 5 -fold increase in total SIV -specific 
ELISpot responses , compared with  control  animals .. In contrast, animals 
vaccinated with the IL -12-enhan ced SIV-MAG pDNA vaccine plus the rVSV 
booster  vaccine  demonstrated a 17 -fold increase in total SIV -spec ific ELISpot 
responses , compared with control animals  (Figure 5). 
 
 
 
                                                                                    HIV-MAG pDNA vaccine  version 5.0 
              Octob er 23, 2014 
 Figure 5: SIV -specific IFN -γ ELISpot responses in immunized SIV -infected rhesus 
macaques   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DDD=an imals vaccinated with an IL -12-enhanced SIV-MAG pDNA vaccine ; DDV=  animals 
vaccinated with IL -12-enhanced SIV-MAG pDNA vaccine plus an rVSV booster  vaccine ; 
Con=control animals ; SIV= simian immunodeficiency virus ; IFN-g=interferon γ; 
ELISpot= enzyme -linked immunospot spot assay ; SFC= spot- forming cells ; PBMCs=  
peripheral bl ood mononuclear cells ; ART=antiretroviral therapy ; Vax=vaccination . 
 
 
In additional studies utilizing a polyfunctional ICS assay, the breadth and 
magnitude of SIV -specific cellular responses return ed to pre -cART levels  in 
vaccinated animals  (data not shown) . Furthermore , animals  vaccinated with the 
IL-12-enhan ced SIV-MAG pDNA vaccine plus the rVSV booster vaccine  
demonstrated de novo  SIV-specific immune responses resulting in an increase 
in the epitope breadth of SIV  gag-specific immune resp onse s, compared with 
animals vaccinated with the IL -12-enhanced SIV-MAG pDNA vaccine alone  
(Figure 6). These data demonstrate that therapeutic immunization of SIV -
infected rhesus macaques with a cytokine -enhanced pDNA prime, rVS V boost 
vaccination regimen augments virus -specific immunity and elicits de novo  
immune responses . 
  
 
 

HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 23 of 72 Figure 6: SIV gag-specific epitope breadth in immunized SIV -infected rhesus 
macaques  
 
DDD =animals vaccinated with an IL -12-enhanced SIV-MAG pDNA vaccine  alone ; DDV=  
animals vaccinated with IL -12-enhanced SIV-MAG pDNA vaccine plus an rVSV booster  
vaccine; Con=control animals; SIV= simian immunodeficiency virus ; ELISpot= enzyme -linked 
immunospot s pot assay ; ART=antiretroviral therapy; Vax=vaccination . 
1.1.3  Summary of Relevant Clinical Studies  
Table 1 below provides a summary of clinical studies evaluating the HIV -MAG 
pDNA vaccine, IL -12 pDNA  vaccine , TDS device, and the rVSV HIV gag 
vaccine. Detailed in formation about these studies can be found in the 
investigator’s brochure documents .   
 

                                                                                    HIV-MAG pDNA vaccine  version 5.0 
              Octob er 23, 2014 
 Table 1: Previous clinical use of the HIV -MAG pDNA vaccine,  IL -12 pDNA, TDS 
device, and the rVSV HIV gag vaccine  
Vaccine 
component  Previous clinical 
experience  Notes  
HIV-MAG pDNA  Healthy adults:  
IAVI B004; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  
HVTN -087; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  To date, approximately 105 healthy adult 
volunteers have received HIV -MAG pDNA 
vaccine delivered by IM EP injection.  
HIV-positive adults:  
ACTG -5281; 
ClinicalTrials.gov identifier: 
[STUDY_ID_REMOVED]  To date, approximately 50 HIV -positive subjects 
have received the HIV -MAG pDNA vaccine 
delivered by IM EP injection.  
IL-12 pDNA  Healthy adults:  
HVTN -060; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  
HVTN -063; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  
HVTN -070; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  
HVTN -080; ClinicalTrials.gov 
identifier:[STUDY_ID_REMOVED]  
IAVI B004; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  
HVTN -087; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  To date, approximately 120 healthy adult 
volunteers have received IL -12 pDNA delivered 
by IM injection and approximately 88 have 
received IL -12 pDNA delivered by IM EP 
injection.  
HIV-positive adults:  
ClinicalTrials.gov identifier: 
[STUDY_ID_REMOVED]  
ACTG -
5281;ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  To date, 10 HIV -positive subjects have received 
IL-12 pDNA delivered by IM injection and 
approximately 50 subjects have received IL -12 
pDNA delivered by IM EP injection.  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 25 of 72 Vaccine 
component  Previous clinical 
experience  Notes  
TDS device  Healthy adults:  
Rockefeller University 
Hospital; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  
 
 
IAVI B004; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  
 
 
Emory Vaccine Trials Unit; 
ClinicalTrials.gov identifier: 
[STUDY_ID_REMOVED]  
 
 
 
 
Walter Reed Army Institute 
of Research; 
ClinicalTrials.gov identifier: 
[STUDY_ID_REMOVED]  24 subjects have been administered a DNA 
vaccine encoding HIV -1 subtype B’/C antigens 
env, gag, pol, nef,  and tat via the TDS device. 
Subjects have received up to 3 administrations 
at total DNA doses of up to 4,000 µg. An 
additional 8 subjects received placebo via the 
TDS device.  
 
75 subjects  have been administered the HIV -
MAG pDNA vaccine with or without the IL -12 
pDNA adjuvant via the TDS device.  
 
30 subjects have been administered a DNA 
vaccine encoding epitopes from  P falciparum 
antigens via the TDS device. Subjects have 
received up to 3 administrations at total DNA 
doses of up to 4,000 µg. An additional 9 
subje cts received placebo via the TDS device.  
 
30 subjects have been administered a DNA 
vaccine encoding antigens from the Hantaan 
and Puumala viruses via the TDS device. 
Subjects have received up to 3administrations 
at total DNA doses of up to 2,000 µg.  
HIV-positive adults:  
ACTG -5281; 
ClinicalTrials.gov identifier: 
[STUDY_ID_REMOVED]  To date, approximately 50 HIV -positive subjects 
have received the HIV -MAG pDNA vaccine with 
or without the IL -12 pDNA adjuvant delivered by 
IM injection via the TDS device.  
Stage IIB-IV melanoma 
subjects:  
Memorial Sloan Kettering 
Cancer Center; 
ClinicalTrials.gov identifier: 
[STUDY_ID_REMOVED]  16 subjects have been administered a DNA 
vaccine encoding epitopes derived from the 
tyrosine -related protein 2 delivered by IM 
injection via the TD S device. Subjects received 
up to 6 administrations at total DNA doses of up 
to 4,000 µg.  
Hepatitis B virus -positive 
adults:  
ClinicalTrials.gov identifier: 
[STUDY_ID_REMOVED]  To date, 9 subjects with chronic hepatitis B virus 
infection have received an antigen -encoding 
DNA vaccine by IM EP injection.  
rVSV HIV gag Healthy adults:  
HVTN -090; ClinicalTrials.gov 
identifier: [STUDY_ID_REMOVED]  To date, approximately 50 healthy adult 
volunteers have received rVSV HIV gag vaccine 
delivered by IM injection.  
IM=intramuscular; EP= electroporation; HIV -MAG pDNA=HIV -1 multiantigen plasmid DNA; IL -12 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 26 of 72 pDNA= interleukin 12 plasmid DNA; rVSV HIV gag=recombinant vesicular stomatitis virus vector 
containing the HIV -1 gag gene; TDS=TriGrid delivery system.  
 
The s afety and adjuvant activity of the IL -12 pDNA alone, or in combination with 
the HIV -MAG pDNA vaccine has been evaluated in several phase I clinical 
trials. The HVTN -080 phase I study evaluated the safety and immunogenicity of 
the PENNVAX™ -B (gag, pol, env ) vaccine, with or without an IL-12 pDNA 
adjuvant , delivered by IM EP injection  in 48 healthy, HIV-negative  adults. 
Participants who receiv ed the gag, pol, env  vaccine alone (group 1), or in 
combination with the IL -12 pDNA adjuvant (group 2 & 3) , developed  both HIV -
specific CD4+  (Figure 7) and CD8+ (Figure 8) T-cell responses. After 3 
vaccinations, 44.4% (4/9) of subjects in group 1  and 80.8% (21/26) of subjects 
in group 2 and 3  responded  (Figure 7 ). The latter response rate was higher than 
after 4 vaccinations with the gag, pol, env  vaccine with the IL-12 adjuvant 
delivered by IM injection without EP ( P=.005; HVTN -070). The response rate for 
the gag, pol, env  vaccine with the IL-12 adjuvant IM+EP was still relatively high 
(53.6% 15/28) 6 months after the third vaccination. These findings validate the 
activity of the IL -12 pDNA adjuvant in combination wit h a DNA plasmid vaccine.  
No serious vaccine -related  safety  concerns  or AE s were  reported.   
 
 
  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 27 of 72 Figure 7: HIV-specific CD4+ intracellular cytokine staining responses from the  
HVTN  080 study  
 
IFN= interferon; IL=interleukin; VAC=vaccination.  
 
  

HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 28 of 72 Figure 8: HIV -specific CD8+ intracellular cytokine staining responses from the  HVTN -
080 study  
 
IFN= interferon; IL=interleukin; VAC=vaccination.  
 
 
Several other ongoing clinical studies evaluating  the HIV -MAG pDNA vaccine or 
the rVSV HIV gag vaccine provide interim safety data. The IAVI-B004 study is a 
double -blind, randomized, placebo -controlled trial assessing  the safety and 
immunogenicity of a n HIV-MAG pDNA vaccine with a recombinant IL -12 pDNA 
adjuvant  followed or preceded by a recombinant Ad35 -GRIN/ENV HIV vaccine 
in healthy , HIV-negative participants. Enrollment is complete and vaccination of 
the first participant occurred in December 2011. To date, no safety concerns 
have been reported . Interim data f ollowing the HIV-MAG pDNA vaccine 
revealed a 36% combined response rate, and the full data set is anticipated in 
January 2013. The ongoing ACTG -5281  trial is a placebo -controlled, dose -
escalation study evaluating the safety and immunogenicity study of a cytokine -
enhanced HIV -MAG pDNA vaccine delivered IM or IM  EP injection in individuals 
with chronic HIV infection. Interim data show a 30% response rate . Enrollment is 
complete and vaccination  of the first subject occurred in April 2011 ; no grade 3 
or 4 AEs have been observed.  
  

HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 29 of 72 The safety and immunogenicity of the rVSV HIV gag vaccine was evaluated in a 
phase I , randomized, double -blind, placebo -controlled, dose -escalation study  
(HVTN -090) of healthy, HIV -negative adults; the study began  in October 2011. 
Groups of 12 participants received the rVSV HIV gag vaccine (n=10/group) at 5 
nominal dose levels (104, 105, 106, 107, and 108 pfu) or placebo (n=2/group)  
delivered by IM injection at 0 and 2 months.  Reactogenicity over 7 days, AEs, 
and viral cultures from  whole blood, urine, saliva, and swabs of oral lesions were 
collected. HIV -1-specific CD4+ and CD8+ T -cell responses to the Gag peptides 
were measured 1 and 2 weeks post -vaccination using an  ICS assay . 
  
As of July 31, 2012, all the vaccinations for this s tudy were completed. As of 
September 11, 2012, the study is still ongoing , and the data are blinded. The 
median age for the  participants is 24 years; 47% of participants are female and 
37% are nonwhite. Local ( Figure 9) and systemic ( Figure 10) reactogenicity was 
self-limited, mild -to-moderate in intensity, and increased with the dose; 
headache was the common AE (52%) followed by malaise/fatigue (43%).  
 
At the highest dose, 92% of  the subjects reported having systemic symptoms, 
including flu -like syndrome (41%), fever (41%), and moderate chills (33%). Of 
the AEs considered related to the study product and reported by 30% of 
participants, the following were experienced by >1 partici pant: lymphadenopathy 
(3), decreased neutrophil count (3), mouth ulceration (3), other oral lesions (3), 
presyncope (3), and upper respiratory tract infection (2). Other AEs considered 
related to the study product and reported by 1 person each were astheni a, 
axillary pain, injection -site hematoma, increased levels of AST, myalgia, 
dizziness, hypoesthesia (at the injection site), oropharyngeal pain, and hot 
flushes. No severe reactogenicity, encephalitis, or product -related SAEs were 
reported. Viral -infectiv ity assays were performed on blood, urine, and saliva 
samples at baseline, 3 days post -vaccinations, and any time symptoms of a viral 
syndrome were reported within 1 week of the vaccination. Saliva samples and 
swabs were collected for all oral ulcerations or oral lesions detected during the 
exam. Cultures of VSV tested negative at all the doses and sites analyzed. Low -
frequency, HIV -specific, CD4+ (9%) , and CD8+ (3%) T -cell responses were 
detected post -vaccination in the first 3 -dose levels. At the 107 pfu dose level, 
HIV gag-specific cell -mediated immune responses were detected in 6 of the 10 
(60%)  vaccine recipients, as measured by IFN -γ ELISpot or IFN -γ/IL-2 ICS 
assay.  These data indicate that immunization with an attenuated, replicating 
rVSV HIV gag vaccine has an acceptable reactogenicity and safety profile to 
date.  
 
The safety and immunogenicity of  the HIV-MAG pDNA vaccine  in combination 
with the IL-12 adjuvant  delivered by IM EP injection  and followed by the r VSV 
HIV gag boost vaccine  is being evaluated in HVTN 087 , an ongoing phase I 
study  of HIV-negative participants. Administration of the  rVSV HIV gag vaccine 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 30 of 72 boost began in February 2012. Thirty of the expected 100 subjects  have been 
enrolled to date, and interim data are anticipated in May 2013. No safety -related 
concerns  have been reported thus far.  In a substudy of  innate immunity , 3 
subjects who had blood collected  24 hours after vaccination with rVSV were 
noted to have transient lymphopenia. The lymphopenia was not as sociated with 
any clinical symptoms and had resolved by the second blood collection  72 hours 
post-vaccination. A similar transient lymphopenia (presumably a result of 
transient changes in lymphocyte migration from blood to lymphoid tissue ) has 
been reporte d following immunization with inactivated influenza virus.32 
  
 
Figure 9: HVTN 090: Maximum local reactogenicity by treatment group  
 
 
 
  
 
 
 
 

HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 31 of 72  
 
Figure 10: HVTN 090: Maximum systemic reactogenicity by treatment group  
 
 
 
1.2 Rationale   
The objective s of this study  are to evaluate the safety and efficacy of the HIV -MAG  
pDNA vaccine prime plus the IL-12 pDNA adjuvant  delivered by IM injection with EP 
in a prime -boost combination with the rVSV  HIV gag booster vaccine. Up to 30 
participants  will be enrolled in the study , half  of whom will receive the study vaccines 
and the other half  will receive placebo. Only s tudy participants who began cART 
during the acute/early phase of HIV infection  are eligible to participate . These 
individuals have been shown to have a relatively preserved immune function, with 
smaller numbers of persistently infected CD4+ T cells, compared with those who 
initiated cART during the chronic phase of infection.33-36  
 
The rationale for using  the proposed doses of the HIV -MAG pDNA vaccine prime and 
IL-12 pDNA adjuvant  is based on the safety and immunogenicity data generated from 
the HVTN -080 and ACTG -5281 trials described in the previous section. Likewise, the  
proposed dose for the rVSV HIV  gag vaccine is based on the safety and 
immunogenicity data from HVTN 090 trial.  Additionally, the TDS device will be used in 

HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 32 of 72 the current study for EP of the DNA prime vaccine/placebo . In vivo EP is beli eved to 
enhance the potency of DNA vaccines by facilitating cellular uptake of DNA.25,27,28 
  
Various assays measuring HIV -specific immune responses have been used to assess 
vaccine immunogenicity. Yet, to date, none of the assays are clinically validated to 
predict vaccine efficacy. Thus, ATI ha s been used in the past to evaluate  the impact 
of therapeutic vaccination on the viral rebound that occurs following cART treatment 
interruption. The use of ATI in the design of this study will allow us to determine if 
vaccination result s in a clinically significant improvement of the immunologic control of 
viral replication, as evidenced by a blunted or absent plasma viral rebound following 
ATI in the vaccine recipients , compared with individual s in the control  group. Based 
on results from prior therapeutic vaccine studies using  ATI,23,24,37,38 as well as a recent 
subgroup analysis of the SMART  study ,39 we feel that a 16 -week ATI , with close 
clinical and laboratory monitoring , is a safe and acceptable strategy to evalu ate the 
efficacy  of the study  vaccination regimen  in this population of HIV-infected adults .    
2 Study Objective  
2.1 Primary Objective  
To evaluate the safety and  tolerability  of the study  vaccine s in subjects who began 
cART during acute or early HIV -1 infection.  
2.2 Secondary Objectives  
To evaluate the efficacy of the study  vaccine s as determined by its effect on rebound 
viremia following  ATI.  
2.3 Exploratory Objectives   
1. To assess the effect of the study  vaccine s on the rate of decay of the HIV -infected, 
CD4+ T -cell reservoir.  
2. To determine the i mmunogenicity of  the study  vaccine s.  
3 Study Design  
3.1 Description of the Study Design  
This is a randomized, 2-arm (1:1), double -blind, placebo -controlled study evaluating 
the safety and efficacy  of an HIV-MAG pDNA vaccine prime  with EP  in combination 
with an IL-12 pDNA  adjuvant and an  rVSV HIV gag booster vaccine  delivere d by 
conventional IM injection,  in subjects  who began cART during  acute or early HIV -1 
infection. Efficacy will be measured in terms of  the effect of the study  vaccination s on 
the plasma viral rebound at 16 weeks following ATI. Because the study is blinded, 
references to active vaccines included below refer EITHER to the active vaccine OR 
matching placebo, unless otherwise specified .  
 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 33 of 72 Vaccination schedule  
Subjects will be randomized to receive placebo or the HIV -MAG pDNA vaccine prime  
(3000 µg) and IL -12 pDNA adjuvant (1000 µg) at week 0, 4, 12, and 36, and the 
rVSV -HIV gag booster vaccine (1x107 pfu) at week 24 and 48  (see Appendix B ).  
 
Each construct ( HIV-1 gag/pol  plasmid or the HIV -1 net/tat/vif , env plasmid) of the 
HIV-MAG pDNA vaccine (1500 µg each) will be mixed with 1000 µg of the IL -12 
pDNA adjuvant and administered as 2 IM injections, 1 into each deltoid, with EP. The 
rVSV HIV gag  booster  vaccine will be administered as 2 IM injections (1 mL each), 1 
into each deltoid.  
 
Analytical  treatment interruption  
After the week 5 6 visit, all subjects  meeting ATI criteria (described below)  will undergo 
an approximately  16-week ATI to determine if th e vaccination strategy result s in an 
improved immune control of the viral replication , as evidenced by a blunted or absent 
viral rebound in the vaccine recipients , compared with the placebo recipients.   
1. ATI will be initiated only in subjects whose CD4 cell count s are >400 cells/  mm3 
and plasma viral levels are below the limit of detection  at week 56. HIV plasma 
viremia and CD4 cell counts will be assessed every 2 weeks during the ATI.  
2. Subjects who do not receive at least one dose of the rVSV HIV  gag boost  or 
matching placebo  will not undergo ATI , but they will continue to be followed for 
safety outcomes.   
3. Any subject w ho develops oral lesions that are positive for VSV by culture or 
PCR will not undergo ATI until the lesions  resolves (for at least 4 weeks) . 
4. Individuals taking non -nucleoside reverse transcriptase inhibitors (NNRTIs) will 
be advised to switch to a protease inhibitor or an integrase inhibitor -based 
regimen  2 weeks prior to the discontinuation of cART to ensure that the washout 
period of antiretroviral agents is roughly equal.    
5. Subjects whose plasma viral levels are below the limit of detection at week 72 
(the end of the ATI period) may elect not to restart  cART until their viral levels 
rise above the limits of detection.  
6. Subjects will be restart ed on cART if they meet any of the following criteria during 
the ATI:  
 A confirmed >30% decline in baseline CD4 cell count or an absolute CD4 cell 
count <350 cells/ mm3. 
 A sustained (≥4 weeks) HIV RNA level of >50,000 copies/m L.  
 Any HIV-related symptoms.  
3.2 Study Endpoints  
3.2.1  Primary Endpoint  
The rate of occurrence  of grade 3 or higher AEs, including SAEs, that, per 
standard criteria ( see safety section ) are:  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 34 of 72  At least possibly related to the test article, and 
 Definit ely NOT related to a factor other than the test article . 
3.2.2  Secondary Endpoint  
The difference in HIV -1 viral load at the end of the  ATI between the vaccine and 
placebo groups.  
3.2.3  Exploratory Endpoints   
1. The frequency and rate of decay of the infectious HIV reservoir between the 
vaccine and placebo groups .  
2. Change from baseline (mean of entry and pre -entry) to post -vaccination in 
the number of IFN -γ/IL-2-generating  CD8+ and CD4+ T -cells/million PBMCs 
in response to gag, pol, env, nef, tat  and vif, as measured by ICS.  
4 Study Population  
4.1 Rationale for Subject Selection  
Individuals who begin cART during early/acute HIV infection have been shown to 
have a relat ively preserved immune function, with smaller numbers of persistently 
infected CD4+ T cells, compared with those who initiated cART during the chronic 
phase of infection. Limiting enrollment to this pool of subjects  maximizes  safety , and it 
helps to determin e whether therapeutic vaccination can significantly augment HIV -
specific immune responses in a clinically meaningful way.   
4.2 Recruitment Plan  
Subjects will be recruited from known cohorts of individuals  who started treatment 
during acute/early HIV infection. Additional local and national recruitment will be done 
using direct mailing to infectious disease physicians, internet ad campaigns, social 
media outlets, and print ads.  
4.3 Subject  Inclusion Criteria  
1. Age, 18-65 years . 
2. Institution of cART w ithin 12  weeks of being diagnosed with acute or early HIV -1 
infection.  
Acute HIV -1 infection  is defined as :   
a.  Detectable plasma HIV -1 RNA levels of >2000 copies/mL with a negative 
result from an HIV-1 EIA, or  
b.  Positive result from an HIV-1 EIA with a negative or indeterminate result from 
an HIV-1 western blot that subsequently evolves to a confirmed positive  
result , or  
c.  Negative result from an HIV-1 EIA within the past 4 months and HIV -1 RNA 
levels of >400,000 copies/m L, in the setting of a potential exposure to HIV -1.  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 35 of 72 Early HIV -1 infection  is defined as:  
a. Negative result from an HIV-1 EIA within 6 months  prior to a  positive result 
from an HIV-1 EIA and an HIV -1 western blot.   
b. Negative result from a rapid HIV -1 test within 1 month  prior to a  positive result 
from an HIV-1 EIA and an HIV -1 western blot.  
c. Presence of low level of HIV antibodies as determined by having a positive 
EIA or a positive Western blot with a non -reactive detuned EI A according to a 
serologic testing a lgorithm for  recent infection.  
 
3. CD4+ cell count >450 cells/mm3 at screening . 
4. Documentation of continuous cART treatment with   suppression of plasma viral 
level below the limit of detection  for >1 year. Subjects with a single “blip” (i.e. , 
detectable viral levels  on cART) prior to randomization may be included provided 
they satisfy the following criteria:  
a. The blips are <400 copies/m L, and  
b. Succeeding viral levels return to levels below the limit of detection on 
subsequent  testing . 
5. Willingness to u ndergo ATI . 
6. Laboratory values within pre -defined limits at screening :  
 Absolute neutrophil count > 1,000/mm3. 
 Hemoglobin levels >10.0 g/dL for men and >9.0 g/dL for women . 
 Platelet count > 100,000/mm3.  
 Prothrombin time (PT) and partial thromboplastin time (PTT) <1.5 upper limit of 
normal (ULN) . 
 Estimated   or a measured  creatinine clearance rate of >60 m L/min as 
determined by the NIH Clinical Center laboratory .  
 AST and ALT  levels of  <2.5 x ULN . 
7. Willingne ss to have samples stored for future research.  
8. Women of childbearing potential must have a negative pregnancy test result.  
 They  must agree to use an adequate form of contraception:  
o Hormonal contraception.  
o Male or female condoms with or without a spermicidal.  
o Diaphragm or cervical cap with a spermicidal.  
o Intrauterine device.  
4.4 Subject  Exclusion Criteria  
1. Allergy to amide -type local anesthetics (bupivacaine [Marcaine], lidocaine 
[Xylocaine] , Mepivacaine [Polocaine/Carbocaine], etidocaine [Duranest], 
prilocaine [Citanest, EMLA cream]) . 
2. Chronic hepatitis B , as evidenced by a p ositive  test for  hepatitis B surface antigen 
(HBsAg) , or chronic hepatitis C virus (HCV)  infection , as evidenced by a positive 
test for HCV RNA.  Subjects with a positive test for H CV antibody  and a negative 
test for HCV RNA  are eligible.  
3. Changes in cART regimen due to virologic breakthrough.  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 36 of 72 4. HIV immunotherapy or vaccine (s) received within 1 year  prior to screening . 
5. Any licensed or experimental non -HIV vaccination (e.g., hepatitis B, influenza, 
pneumococcal polysaccharide) received within 4 weeks prior to study entry.  
6. Interruption  of cART for >3  month s since its initiation.  
7. Pregnancy or p lanned pregnancy during the study period or b reastfeeding.  
8. Any active malignancy that may require systemic chemotherapy or radiation 
therapy . 
9. Immunosuppressive medications received within 6 months before the first study 
vaccination (Not excluded: [ 1] corticosteroid nasal spray for al lergic rhinitis; [ 2] 
topical corticosteroids for mild, uncomplicated dermatitis; or [ 3] oral/parenteral 
corticosteroids administered  for non -chronic conditions not expected to recur 
[length of therapy ≤10 days , with completion in ≥30 days prior to enrollme nt]). 
10. Evidence of hepatic decompensation in subjects  with cirrhosis : history of ascites, 
hepatic encephalopathy, or bleeding esophageal varices, or screening laboratory 
results with any of the following:  
a. International normalized ratio  of ≥1.5 x ULN. 
b. Serum albumin <3.2  g/dL. 
c. Serum total bilirubin >1.8 x ULN, unless history of Gilbert's disease or deemed 
related to treatment with atazanavir . 
11. History or other clinical evidence of :  
a. Significant or unstable cardiac disease (e.g., angina, congestive heart failure, 
recent myocardial infarction, significant arr hythmia) . 
b. Severe illness, malignancy, immunodeficiency other than HIV, or any other 
conditions that, in the opinion of the investigator, would make the subject 
unsuitable for the study.  
c. AIDS -defining co ndition.  
12. Known allergy or sensitivity to the components of the investigational therapy.  
13. History of significant cardiac arrhythmia  (e.g., supraventricular tachycardia, 
ventricular tachycardia, and atrial fibrillation /flutter) . 
14. Active drug or alcohol use or any other pattern of behaivor  that, in the opinion of 
the investigator,  would interfere with adherence to study requirements.  
15. Any active  systemic  inflammatory or autoimmune disease or condition.  
16. Presence of implanted electronic medical device (e.g., pac emaker, implantable 
cardiac  defibrillator) or surgical/traumatic metal implant in the upper limb and/or 
upper torso.  
17. Neurological  or neuropsychiatric disorder  that may interfere with the assessment 
of safety (e.g., frequent recurring headaches , for example,  a pattern of >1 
headache /month affecting activities of daily living/work, frequent or 
severe/complicated migraines, cluster headaches) ; or history of encephalitis, 
narcolepsy, stroke with sequelae, moderate/severe major depressive disorder, 
moderate/sever e bipolar disorder, seizure disorder . 
18. Deltoid skinfold measurement s (by caliper ) of >40 mm . 
19. Body mass index >40 . 
 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 37 of 72 Co-enrollment guideline s: Co-enrollment in other trials is restricted, other than  
enrollment  on observational studies or those evaluating the use of a licensed 
medication. Study staff should be notified of co -enrollment , as it may require the 
approval of the principal investigator.  
5 Justification for Exclusion of Women and Children (Special Populations)   
Exclusion of women:    
 Pregnancy:  Pregnant women are excluded from this study because the effects of the 
HIV-MAG pDNA vaccine  prime /IL-12 pDNA adjuvant/rVSV HIV gag booster vaccine 
on the developing human fetus are unknown with the potential for teratogenic or 
abortifacient effects .   
 Breastfeeding: Because there is an unknown but potential risk for AEs in nursing 
infants secondary to the treatment of the mother with the HIV -MAG pDNA vaccine  
prime /IL-12 pDNA adjuvant/rVSV HIV gag booster vaccine , breastfeeding should be 
discontinued if the mother is treated with these study agents . 
Exclusion of children : Because there are insufficient data regarding the dosing or AEs 
available in adults for the study agents  to judge the potential risk in children, they are 
excluded from this study.  
6 Study  Agent/Interventions   
6.1 Disposition and Dispensation  
The s tudy agents  will be distributed by Profectus, Inc. to  the NIH Central Pharmacy 
according to standard pharmacy procedures.  
6.1.1  Formulation, Packaging , and Labeling   
Each study product (i.e., HIV-MAG pDNA vaccine  prime , IL-12 pDNA adjuvant, 
and rVSV -HIV gag booster vaccine ) will be individually vialed and labeled with 
the study product name, lot number, concentration , and recommended storage 
conditions.  
6.2 Study Agent Storage and Stability   
The HIV -MAG pDNA vaccine prime and the IL-12 pDNA adjuvant should be stored 
and refrigerated at 2˚C to 8˚C, if not immediately administered. When constructs are 
mixed and administered in combination, it is recommended that the combined 
formulation be used within 4 hours after mixing. The proposed expiration period for 
the HIV -MAG pDNA vaccine prime and the IL -12 pDNA adjuvant is 12 months from 
the date of formulation. Batches may be evaluated for stability at the expiration time 
point to justify their use p assed the expiration date.  
 
Vials containing the rVSV -HIV gag booster vaccine vector should be stored at -80˚C. 
No more than 4 h ours prior to use, vaccine vials should be placed  at room 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 38 of 72 temperature  to thaw the vaccine formulation  rapidly . Thawed vaccine can either be 
used immediately for inoculation or be stored at 2 ˚C-8˚C for up to 4 h ours prior to 
inoculation. The proposed expiration period for the booster vaccine  is 12 months from 
the date of formulation. Batches may be evaluated for stability at the expiration time 
point to justify their use passed the expiration date.  
Sodium chloride for injection (USP 0.9%)  will be used as a control substance for the 
placebo group. The vials must be stored as directed by the manufacturer of the 
product.  
6.3 Preparation, Administration, and Dosage of Study Agent/Intervention(s)  
 
Description  
HIV-MAG pDNA vaccine prime  composed of the HIV -1 gag/pol  plasmid and HIV -
1 nef/tat/vif, env  plasmid  
HIV-MAG pDNA HIV-1 gag/pol plasmid   
The HIV -MAG pDNA HIV-1 gag/pol  plasmid is a clear, colorless solution enclosed  in 
2-mL single -use vial s. Each 2 -mL vial contains 0.8±0.04 mL of the HIV-1 gag/pol  
pDNA at a concentration of 3 mg/mL in 30  mM citrate buffer pH 6.5 , containing 150 
mM NaCl, 0.015 ethylenediaminetetraacetic acid ( EDTA ), and 0.25% bupivacaine -
HCl.  
The product is contraindicated in participants with known hypersensitivity to 
bupivacaine  or any other amide -type local anesthetic . 
HIV-MAG pDNA HIV-1 nef/tat/vif, env plasmid   
The HIV -MAG  pDNA  HIV-1 nef/tat/vif, env  is a clear, colorless solution packaged  in 2-
mL single -use vial s. Each 2 -mL vial contains 0.8±0.04 mL of the HIV-1 nef/tat/vif, env  
pDNA at a concentration of 3 mg/mL in 30  mM citrate buffer pH 6.5 , containing 150 
mM NaCl, 0.01 5 EDTA, and 0.25% bupivacaine -HCl.  
The product is contraindicated in participants with known hypersensitivity to  
bupivacaine  or any other amide -type local anesthetic . 
IL-12 pDNA adjuvant   
The IL-12 pDNA adjuvant  is a clear , colorless solution packaged in 2-mL single -use 
vials. Each 2 -mL vial contains 0.9±0.04 mL of IL -12 pDNA at a concentration of 2 
mg/mL in 30 mM citrate buffer pH 6.5 , containing 150 mM NaCl, 0.01% EDTA , and 
0.25% bupivacaine -HCl.  
The product is contraindicated in participants with known  hypersensitivity to 
bupivacaine  or any other amide -type local anesthetic .  
rVSV HIV gag booster vaccine  
The r VSV-HIV gag booster vaccine is a clear , colorless solution  packaged in 3-mL 
single -use vials.  Each 3 -mL single -use vial contains 1.3 mL (5x106 pfu/mL) of the 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 39 of 72 vaccine  formulated in an aqueous liquid phosphate buffer containing gelatin as a virus 
stabilizer .  
Control product  
Sodium chloride for injection  (USP 0.9% ) will be used as a control substance for the  
placebo group. The volume of sodium chloride  administered will be the same as that 
for the study vaccine compon ents.   
Dosing and administration  
HIV-MAG pDNA vaccine prime will be administered at a dose of 3000 µg (1500 µg  
of the HIV -1 gag/pol  plasmid and 1500 µg  of the HIV -1 net/tat/vif , env plasmid)  at 
week 0, 4, 12, and 36. Each construct of HIV -MAG pDNA vaccine (1500 µg each) will 
be mixed  and combined  with 1000 µg  of the IL -12 pDNA adjuvant. The resulting 
mixture will be divided  into 2 IM injections  and administered as  0.75 mL IM injection in 
the left deltoid and 0.75 mL IM injection in the right deltoid with EP using the TDS 
device.  
IL-12 pDNA adjuvant will be mixed with the HIV -MAG pDNA vaccine prime, as noted 
above, and administered at a dose of 1000 µg (500 µg in each IM inject ion) at week 
0, 4, 12, and 36.  
rVSV HIV gag booster vaccine --The total dose , 1x107 pfu, will be  administered as 1 
mL (5x106 pfu) IM injection in the left deltoid and 1 mL (5x106 pfu) IM injection in the 
right deltoid at week 24 and 48.  
Placebo for the IL-12 pDNA adjuvant and HIV -MAG pDNA vaccine ( sodium chloride 
for injection , USP 0.9%) will be administered as 0.75 mL IM injection in the left deltoid 
and 0.75 mL IM injection in the right deltoid at weeks 0, 4, 12, and 36 with EP using 
the TDS device.  
Placebo  for the rVSV HIV gag (sodium chloride for injection , USP 0.9%) will be 
administered as 1 mL IM injection in the left deltoid and 1 mL IM injection in the right 
deltoid at week 24 and 48.  
 
Dose Adjustments/Modifications/Delays  
Delaying vaccinations for a participant  
Under certain circumstances, a participant’s scheduled vaccination will be delayed. 
The factors to consider when such a decision needs to be made include , but are not 
limited to , the following:  
 Live attenuated vaccines , other than influenza vaccine , received within 30 days 
prior to the study  vaccination (s). 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 40 of 72  Influenza vaccine or any vaccines that are not live attenuated (e .g., 
pneumococcal  vaccines ) received within 14 days prior to the study  
vaccination (s). 
 Allergy treatm ent with antigen injections received within 30 days prior to the 
study vaccination(s).  
 Abnormal vital signs or clinical symptoms prior to the study vaccinations that may 
interfere with  assessment of the vaccine reaction.  
In order to avoid vaccination delay s and missed vaccinations, participants who pl an to 
receive licensed vaccines or allergy treatments  will be counseled to schedule receipt 
of these substances outside the intervals indicated above, when ever possible. 
Because the effects of these substances on the safety and immunogenicity 
assessments and their interactions with the study vaccines are unknown, the 
substances should also be avoided in the 2 -week interval between a study 
vaccination and completion of the next scheduled post -vaccination follow -up visit.  
 
Participant departure from the vaccination schedule  
Every effort should be made to follow the vaccination schedule according to  the 
protocol. With the exception of the first pDNA vaccination, i f a participant misses a 
vaccina tion and the 14-day window period for the vaccination has passed, that 
vaccination cannot be administered . The participant should be asked to continue with 
the remaining study visits. The participant should resume the vaccination schedule for 
the next vacc ination unless there are circumstances that require further delay or 
permanent discontinuation of the vaccination.   
 
If a participant receives only 1 of the 2 scheduled injections  (i.e. half  of the vaccine/  
placebo  dose ), the principal investigator will determine whether the vaccination 
schedule can be resumed with the next scheduled injection.  
 
Tracking of dose  
The vials for the HIV -MAG pDNA vaccine prime, IL -12 pDNA adjuvant, and rVSV -HIV 
gag booster vaccine will be labeled a s described in Section 6.1.1  with the assigned 
study subject numbers and no other forms of subject identifiers, and they will be kept 
as directed by the sponsor. Tracking will be based on the number of vials used for 
each subject, accounting for any amount left in the last vial for e ach subject.  
6.4 Concomitant Medications and Procedures   
All concomitant prescription medications taken during study participation will be  
documented  in Clinical Research Information Management System of the NIAID 
(CRIMSON ). For this protocol, a prescription medication is defined as a medication 
that can be prescribed only by a properly authorized/licensed clinician.  Medications 
to be reported in CRIMSON  documents  are concomitant prescription medications, 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 41 of 72 over-the-counter med ications , and non -prescription medications taken at the time of 
AEs (all grades).  
6.5 Prohibited Prescription Medications and Procedures  
Treatment with immunosuppressive medications received within 6 months before the 
first study vaccination (not including [1] corticosteroid nasal spray for allergic rhinitis; 
[2] topical corticosteroids for mild, uncomplicated dermatitis; or [ 3] oral/parenteral 
corticosteroids given for non -chronic conditions not expected to recur  ̵length of 
therapy ≤10 days) will not be permi tted unless disc ussed with and approved by the  
principal invest igator . 
7 Study Schedule  
For all the study visits, unless otherwise specified, subjects will come to the NIH Clinical 
Center to undergo the procedures.  Unless otherwise specified, t he visit window for the 
post-entry study visits is ± 5  days. 
7.1 Screening  
Screening may occur over the course of several contacts/visits, up to and including , 
before the first vaccination on day 0  (week 0) . All inclusion and exclusion criteria must 
be assesse d within 8 weeks before enrollment, unless otherwise specified in the 
eligibility criteria.   
After signing informed consent, subjects will undergo the following procedures:  
 Medical history and a targeted physical exam ination , including weight, vital signs, 
and a symptom -directed evaluation based on symptoms or complaints reported by 
each participant.  
 Assessment of concomitant medications.  
 Deltoid skinfold measurement . 
 Blood collection for :  
o HBsAg . 
o Rapid plasma reagin test . 
o Anti-HIV and anti -HCV  antibody tests . 
o Complete blood count ( CBC ) with differential , PT, activated PTT. 
o Chemistry panel to include: ALT, AST, alkaline phosphatase, creatinine, 
CPK, total and direct bilirubin, and serum albumin levels.  
o Flow cytometry panel (includes CD4+ cell count) .  
o Plasma HIV and HCV  viral RNA levels.  
o Storage of PBMC s. 
 Urinalysis . 
 Serum or urine pregnancy test  (for women of child -bearing potential) .   
 Electrocardiogram  (ECG).  
7.2 Enrollment/Baseline  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 42 of 72 During enrollment a t week 0 , eligible subjects will be randomized in a 1:1 ratio to  
receive placebo or the HIV -MAG pDNA vaccine prime plus the IL -12 pDNA adjuvant 
and the rVSV -HIV gag booster vaccine . The first dose of placebo or the vaccine 
regimen will be administered at this visit , and enrollment is defined as the day of 
receipt of the first study vaccine.  
During week 0 , subject s will undergo the followin g procedures  (prior to the first study 
vaccination) : 
 Medical history and a targeted physical examination, including weight, vital signs, 
and a symptom -directed evaluation based on symptoms or complaints  reported by 
each participant.  
 Assessment of concomitant medications.  
 HIV transmission risk behavior assessment  and counseling  
 Leukapheresis  for research studies  (see Section 8.2) 
 Blood collection for:  
o Flow cytometry panel (includes CD 4+ cell count) . 
o Plasma HIV viral RNA levels . 
o Serum baseline VSV serology . 
o HLA typing . 
o Storage of s erum  and PBMC s. 
o CBC  with differential . 
o Chemistry panel s, to include: ALT, AST, alkaline phosphatase, creatinine, 
CPK, total and direct bilirubin, and serum albumin levels . 
 Serum or urine pregnancy test  (for women of child -bearing potential) .   
 Assessment of reactogenicity parameters (following the first study vaccination) as 
described in Section  8.1. 
 Instructions on the use of a symptom log/diary card.  
7.3 Randomization  
The Pharmaceutical Development Section of the NIH Clinical Center  pharmacy will 
generate a 1:1 randomization scheme for the protocol. A table of random numbers will 
be used.   A set of numbers, equivalent to the proposed “N” will be selected.  An 
appropriate block will be chosen, based on the “N”.   Within that block, the highest 
numbers will be assigned to one treatment assignment (vaccine), while the lowest 
numbers will be assigned to the alternate treatment (placebo).    
7.4 Vaccination Phase  
Subje cts must  continue on their current cART regimen  during the vaccination phase .  
 
Subjects will be administered either placebo or the HIV-MAG vaccine plus the IL -12 
pDNA adjuvant at week  0, 4, 12, and 36, and the rVSV HIV gag booster vaccine 
(1x107 pfu) at week 24 and 48.  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 43 of 72 During the  visits  at week 4, 12, 24, 36, 48, and 56 , subjects will undergo the following 
procedures:  
 Medical history and a targeted physical examination, including weight, vital signs, 
and a symptom -directed evaluation based on symptoms  or complaints  reported by 
each participant.  
 Assessment of concomitant medications .  
 Assessment of reactogenicity parameters ( at week 4, 12, 24, 36, and 48  only; see  
Section  8.1). 
 Assessment of any new or unresolved AEs/intercurrent illnesses . 
 Blood collection for:  
o CBC  with differential . 
o Chemistry panels, to  include: ALT, AST, alkaline phosphatase, creatinine, 
CPK, t otal and direct bilirubin, and serum albumin levels . 
o Flow cytometry panel (includes CD4+ cell count) . 
o Plasma HIV viral RNA levels . 
o VSV serology (at week  26 and 50  only). 
 Leukapheresis for research studies including , but not limited to , quantitative co -
cultures of CD4+ cells and related immunologic and virologic studies ( at week 36  
and 56  only). 
 Serum or urine pregnancy test  (for women of child -bearing potential) .   
 Evaluation of symptom log/diary card.  
 HIV transmission risk behavior assessment and counseling (week 56 only)  
 
During the visits at week 14, 26, 38, and 50, blood will be collected for  flow cytometry, 
CBC,  and storage of plasma  and PBMCs  for assessment of immunogenicity . For 
select subjects residing outside the local  (Bethe sda, MD)  area, blood samples for 
CD4 counts , and storage,  may be collected  at their local clinic s and sent to the NIH 
Clinical Center for testing  and storage .  
 
Any participant who develops oral ulcers within 7 days post -vaccination with the rVSV  
vaccine/p lacebo will have swabs from the oral lesion(s) collected and sent for VSV 
culture and PCR (see section 8.1 ). 
7.5 Post -Vaccination ATI Phase  
The ATI phase will begin after the visit at week 56 and will continue until week 72 . 
During this phase, CD4 counts and HIV viral RNA levels will be measured every 2 
weeks.   
For select subjects residing outside the local  (Bethesda, MD)  area, blood samples for 
CD4 counts and HIV viral RNA levels may be collected  at their local clinic s and sent 
to the NIH Clinical Center via overnight shipment  for testing .  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 44 of 72 All subjects will return to the NIH Clinical Center at week 64 and 7 2 for the following 
procedures:  
 Medical history and a targeted physical exam ination, including weight, vital signs, 
and a symptom -directed evaluation based on symptoms or complaints reported by 
each participant.  
 Assessment of any new or unresolved AEs/intercurrent illnesses.  
 Blood collection for:  
o CBC  with differential . 
o Chemistry panel s to include: ALT, AST, alkal ine phosphatase, creatinine, 
total and direct bilirubin, and serum albumin levels . 
o Flow cytometry panel (includes CD4+ cell count) . 
o Plasma HIV viral RNA levels.  
o Serum or urine pregnancy test (for women of child -bearing potential).   
o HIV genotype (week 72 o nly, or prior to restarting cART ). 
o Storage of s erum and PBMCs . 
If a subject develops one or more criteria for ending ATI (see Section 3.1), he/she will 
be asked to  return for an unscheduled visit for assessment and confirmation of the 
laboratory/clinical abnormalit y. If the criter ia for ending ATI are met, the subject will 
restart cART and will continue to be followed for 6 months after restarting cART , and 
he/she will  undergo the schedule of procedures listed in Section 7.6 below  under 
week 84 and 96 .  
7.6 Post -Vaccination, Post -ATI Phase  
After the  visit at week 72, subjects  will restart their cART regimen  and will continue 
treatment through week 96  (end of study) .  
At week 76 and  80, blood will be collect ed for CD4+ cell counts and HIV viral RNA 
levels . For select subjects residing outside the local area, bl ood samples may be 
collected at local clinic s and sent to the NIH Clinical Center via overnight shipment for 
testing.  
 
All subjects will return to the NIH Clinical Center a t week 84 and 96  to undergo the 
following procedures:  
 Medical history and a targeted physical exam ination, including weight, vital signs, 
and a symptom -directed evaluation based on symptoms or complaints reported by 
each participant.  
 Assessment of any new or unresolved AEs/intercurrent illnesses.  
 Blood collection for:  
o CBC  with dif ferential . 
o Chemistry  panel s, to include: ALT, AST, alkaline phosphatase, creatinine, 
total and direct bilirubin, and serum albumin levels . 
o Flow cytometry panel (includes CD4+ cell count) . 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 45 of 72 o Plasma HIV viral RNA levels . 
o Storage of s erum and PBMCs .  
 
If HIV vi ral RNA levels are detectable  at week 84, the testing will be repeated at week 
88 and week 92 (if detectable at week 88) . 
 
For subjects who meet criteria to re -start cART  prior to week 72  (described in  
Section  3.1),  HIV RNA levels will be done every 4 weeks until levels fall below the 
limit of detection.  
 
As described in Section 3.1, subjects whose HIV RNA levels are below the limit of 
detection (<40 copies/ml) at week 72 may elect to continue on the ATI phase of the 
study and have their CD4 count and HIV RNA levels monitored every 2 weeks until 
HIV RNA lev els become detectable or until the final study visit at week 92.  
 
If a subject with HIV RNA levels above the limit of detection (>40 copies/ml) at week 
72  refuses  to restart cART (despite the protocol team’s  recommendation to do so ), 
the subject may continue to have CD4 count and HIV viral levels monitored every 2 
weeks until cART is restarted . If the subject continues to have measurable virema at  
the week 84  visit and continues to refuses  to restart cART, the subject will be 
removed f rom the study and returned to the care of their private physician .  
 
For pu rposes of data analysis in the  subjects  described above , the HIV RNA level 
obtained at week 72 will be used for the secondary endpoint analysis .  
8 Study Procedures/Evaluations  
8.1 Clinical Evaluations  
 Medical history and physical examination  
 Deltoid skinfold measurement: The skin -pinch test measures the thickness of 
the cutaneous and subcutaneous tissue at the injection site of both upper arms 
(medial deltoid muscles). This measurement will be used to determine the depth of 
the injection for each eligible subject to ensure IM administration of the vaccine/  
placebo prior to the first vaccination. The skin -thickness range and corresponding 
depth settings on the TDS -IM are described in the TDS-IM: Instructions for Use  
Manual .   
 Phlebotomy : Blood will be collected for routine  serologic,  hematologic , and clinical 
chemistry evaluations  as described in Section  7.  
 Oral swabs : Subjects who develop oral lesions  up to 7 days post -vaccination with 
rVSV/placebo  will have the lesions  tested  for the presence of VSV shedding via 
RT/PCR analysis and in vitro virus culture via the rVSV viral infectivity assay. Vero 
cell cultures will be incubated with participant samples and examined by 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 46 of 72 microscopy for the presence of VSV -induced cytopathic effec ts. If cytopathic 
effects are observed, VSV titrations will be performed by a plaque assay to quantify 
the amount of virus being shed in test samples. Nucleotide sequence analysis will 
be performed on amplified virus from test sample(s) to verify the prese nce of VSV. 
All viral infectivity assays will be performed by Profectus Biosciences.  
 Assessment of reactogenicity : For all participants, reactogenicity  assessments 
will be  performed at baseline prior to any study vaccinations and subsequently 
after each vaccination. All reactogenicity symptoms will be  followed until resolution 
and graded according to the Division of AIDS (DAIDS) Table for Grading the 
Severity of Adult and Pediatric Adverse Events, Version 1.0, December 2004 
(Clarification Augus t 2009) . 
The reactogenicity assessment period is 3 full days following each HIV -MAG pDNA 
vaccine/placebo injection and 7 full days following the rVSV- HIV gag vaccine/  
placebo injection according to  the schedule shown in Table 2 below . Participants 
will be  instructed to record symptoms using a post -vaccination symptom log /diary 
card (see Appendix D ) and to contact the site daily during the assessment period. 
Participants will also be  instructed to contact the clinic for events that occur during 
the period between each vaccination and the next scheduled visit. In general, a ny 
participant who self -repor ts a post -vaccin ation reaction greater than moderate  will 
be evaluated  by a clinician within 48 hours after onset, unless the reaction is 
improving and/or has completely resolved.  
Table 2: Schedule of reactogenicity assessments  
Day Time  Performed by  
0a Pain asses sment  immediate: post -vaccination  OP8 staff  
 Pain asses sment  25-60 minutes: post -vaccination  OP8 staff  
1 Reactogenicity between 12:00 AM and 11:59 PM day 1  OP8 staff or participant  
2 Reactogenicity between 12:00 AM and 11:59 PM day 2  OP8 staff or participant  
3 Reactogenicity between 12:00 AM and 11:59 PM day 3  OP8 staff or participant  
4-7 Reactogenicity between 12:00 am and 11:59 pm days 4 -7, for 
VSV HIV gag vaccine/placebo only  OP8 staff or participant  
VSV=vesicular stomatitis virus . 
aDay of vaccination . 
8.2 Research  Evaluations  
Leukapheresis:  Will be performed for research studies including, but not limited to, 
measurements of  the  frequency of CD4+ T cells carrying replication -competent HIV 
by quantitative coculture assays. These studies will determine the rate of decay of the 
CD4+ T-cell reservoir. If leuk apheresis cannot be performed for technical reasons 
(e.g. poor venous access ) 80 ml of heparinized blood will be drawn instead.  
Other research evaluations measuring the effect of the vaccinations on the HIV 
pathogenesis may include : 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 47 of 72  Frequency of CD4+ T cells carrying HIV proviral DNA and cell -associated HIV 
RNA . 
 HIV burst size in CD4+ T cells in the presence of autologous CD8+ T cells . 
 Magnitude and breadth of HIV -specific CD4+ and CD8+ T-cell responses.  
 T-cell activation and soluble markers of inflammation . 
 Residual (1 -40 copies/m L) plasma viremia . 
 VSV serology:  The VSV neutralizing antibody titer will be evaluated to determine 
the magnitude of the immune response elicited to the vector.  
 HIV viral RNA levels . 
 Flow cytometry with CD4+ cell count . 
9 Potential Risks and Benefits  
9.1 Potential Risks  
General risks associated with vaccination/ DNA vaccination  
Possible risks associated with vaccines include fever, chills, rash, arthalgias/myalgias , 
nausea, headache, dizziness, fatigue , and anaphylaxis . The theoretical risks of DNA 
vaccination could include the possible integration of plasmid DNA into the host  
genome, resulting in mutations , problems with DNA replication , triggering of 
autoimmune responses, and activation of cancer -causing genes.  To date, there is no 
clear evidence  from numerous clinical trials  for integration of plasmid DNA into the 
host genome triggering autoimmune disease/neoplastic disease.   
 
HIV-MAG pDNA vaccine   
The HIV-MAG  pDNA vaccine ha s been administered to approximately 150 individuals 
to date , and it appear s to be well tolerated.  The vaccine plasmids HIV -1 gag/pol and 
HIV-1 nef/tat/vif, env are formulated in 0.25% bupivacaine , thus, there is a risk of 
allergic reactio n from bupivacaine , including nausea, vomiting, chills, rash, urticaria, 
angioedema, bronchospasm, or anaphylaxis.  Significant AEs,  including cardiac arrest 
and death , have occurred following intravenous delivery of bupivacaine. In most 
cases, th e events o ccurred following  use of bupivacaine at a dose of 1.6 mg/kg. In the 
current study , bupivacaine will be  administered IM at a dose of 2.5 mg/m L (maximum 
2 mL or 5 mg). A 7 0-kg pe rson would receive a dose of 0.07  mg/kg per dose . 
Participants with a history of  allergic reaction to amide -type local anesthetics 
(bupivacaine, lidocaine, mepivacaine, etidocaine, prilocaine) will be excluded  from the 
study . 
                                                                                                                                                                          
IL-12 pDNA adjuvant    
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 48 of 72 The IL -12 plasmid adjuvant is also formulated in 0.25% bupivacaine, so the risks 
associated with bupivacaine are also associated with this product (see HIV -MAG 
pDNA above).  
In addition, it is possible that administration of the IL -12 pDNA adjuvant might elicit 
antibodies that could affect the native IL -12 cytokine. In the HVTN -080 study, an 
assay was performed to test for the presen ce of IL -12 neutralizing antibody following  
administration of the IL -12 pDNA (1,000 µg or placebo). Results showed that 1 
subject tested positive for IL -12 neutralizing antibodies following vaccination (49 
NU/mL), but the subject also had a high levels (39 NU/mL) at baseline. Another 
subject was po sitive for IL -12 neutralizing antibodies at baseline (31 NU/mL) followed 
by lower post -vaccination levels (9 NU/mL).   
 
Electroporation  
EP has been associated with transient muscle contractions and injection -site 
discomfort , such as pain, soreness, bruising,  redness, swelling, itching, and stiffness 
of the upper arm . The procedure also carries the theoretical  risks of electrical injury or  
infection at the injection site, disruption of the function of the implanted electronic 
medical devices (e.g., pa cemaker, implantable cardi ac defibrillator), or the 
exacerbation of cardiac arrhythmias. Participants with a history of clinically significant 
cardiac arrhythmia (excluding sinus arrhythmia) , pacemakers, implantable cardi ac 
defibrillator,  or certain metal implants will be excluded.  Electroporation with the TDS 
device has been used in about 280 people to date  who participat ed in clinical trials . 
Adverse responses reported in association with use of the device have been largely 
limited to acute discomfort during  the procedure application , and transient injection -
site soreness of mild –to-moderate severity for up to  1 week following administration.  
 
rVSV HIV gag  
Results from a randomized, double -blind, placebo -controlled, dose -escalation study of  
60 healthy volunteers ( HVTN 090 ) showed that l ocal ( Figure 9) and systemic ( Figure 
10) reactogenicity was self -limited, mild -to-moderate in intensity, and increase d with 
dose; headache was the common AE (52%) followed by malaise/fatigue (43%). At the 
highest dose  (108 pfu), 92% of the subjects reported having systemic symptoms, 
including flu -like syndrome (41%), fever (41%), and moderate chills (33%). Of the AEs 
considered related to the study product and reported by 30% of participants, the 
following were experienced by >1 participant: lymphadenopathy (3), decreased 
neutrophil count (3), mouth ulceration (3), other oral lesions (3), presyncope (3), and 
upper respira tory tract infection (2). Other AEs considered related to the study product 
and reported by 1 person each were asthenia, axillary pain, injection -site hematoma, 
increased levels of AST, myalgia, dizziness, hypoesthesia (at the injection site), 
oropharyngea l pain, and hot flushes. No severe reactogenicity, encephalitis, or 
product -related SAEs were reported.  
 
VSV infection in humans is rare, but it can occur when animal handlers and 
veterinarians come in close contact with infected livestock and through ina dvertent 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 49 of 72 exposure of laboratory personnel. The most common portals of infection in humans 
are skin and mucous membranes of the nose, mouth, and eyes, although there is also 
serological evidence that suggests that some vesiculoviruses may be directly 
transm itted to humans through insect bites. Human infection with VSV can either be 
asymptomatic , or it may lead to disease symptoms, which include myalgia, headache, 
fatigue, oral ulcers , and fever that resolve in 3 –5 days without complications. Because 
the vaccine candidate is a live, replication competent vector, there is a theoretical risk 
of human disease , including neurologic manifestations . The vaccine vector was 
specifically attenuated to eliminate neurovirulence , which has been tested  in sensitive 
animal models  (refer to the investigator’s brochure for more information on 
neurovirulence testing) . Furthermore, no evidence of encephalitis or other neurologic 
events was observed following administration of the vaccine  in subjects participating 
in the HVTN  090 trial. However, as a precaution, subjects may not participate in the 
current study  if they have a neurological/neuropsychiatric disorder that could be 
confused with reactions to the VSV HIV gag vaccine , or could interfere with the 
assessment of safety .  
 
There is also a hypothetical risk of eliciting autoimmune responses in vaccine 
recipients. This risk is based on the identification of a peptide octamer and other 
shorter peptides in the Indiana serotype VSV (VSV IN) N protein that are very similar in 
sequence to peptides found in Ro60kD, which bind the anti -Ro/SSA antibodies found 
in sera of subjects  with systemi c lupus erythematosis (SLE) .40 Antibodies that bind the 
Ro protein can also be elic ited in rabbits that are hyperimmunized with purified VSV IN 
N protein .41 In addition, antibodies have been detected in SLE subjects  that cross 
react with the VSV IN M and , to a lesser extent , N core proteins , but at a much lower 
freque ncy to the VSV IN G protein .42 However, it is not clear what these observations 
mean since antibodies that react to the peptide octamer in Ro60kD account only for a 
small minority of the anti -Ro60kD auto -antibodies in SLE subjects .43 Also, the 
detection of antibodies in the sera of SLE subjects  that react with the VSV IN M and N 
proteins , but not with the G protein , is puzzling, because the VSV G protein has 
strong antigenic properties and typically elicits a very  robust and dura ble humoral 
immune response . Furthermore, the epidemiology of SLE does not support a specific 
role for VSV IN as a causative agent, since VSV IN is found only in the Americas , and 
the frequency of SLE in t he United Kingdom  and the USA is very  similar .44 Based on 
the  literature  currently available , there is no convincing evidence that infection with 
VSV IN leads to the development of SLE.  
 
Analytical treatment interruption  
The risks  from a 16-week ATI performed  under close virological and immunological 
monitoring are minimal in this subject  population. There is a theor etical risk that ATI 
could lead to the development of  HIV drug resistance. This may be a particu lar 
concern for individuals taking NNRTIs . However , this  potential  risk with NNRTIs  is 
essentially  eliminated by undertaking the procedures described in Sectio n 3.1. Given 
the study population, the short duration of  the ATI, the frequency of immunological 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 50 of 72 and virological monitoring, and strict criteria for restarting cART, it is extremely 
unlikely that the ATI will lead to the development of any opportunistic infections or 
AIDS -defining conditions.  
 
Leukapheresis  
The potential  risks associated with  leukapheresis  include lightheadedness, dizziness , 
possible fainting,  tingling around the mo uth and in the fingers and toes,  nausea, chills, 
vomiting , mild mu scle cramps,  loss of <1  pint of blood , or pain, bruising , or discomfort  
at the needle insertion  sites. More serious , but rare , complications include  nerve 
damage at the needle insertion site,  seizures and  air embolism. Most procedures are 
performed without an  incident. Blood components removed during leukapheresis  are 
generally replaced b y the body within a few hours or  a few days. No infections 
associated with this procedure have been reported  in thousand s of cases performed 
over the last 10 years at the NIH.   
 
Phlebotomy  
This may be associated with discomfort, bruising, local hematoma formation and, on 
rare occasions, infections , lightheadedness,  and fainting. The amount of blood drawn 
for research purposes will be within the limits allowed for adult subjects by the NIH 
CC (Medical Administrative Policy 95 -9: Guidelines for Limits of Blood Drawn for 
Research Purposes in the Clinical Center: 
http://internal.cc.nih.gov/policies/list_policies.asp?index=med_chrono ). 
 
HLA typing  
Some HLA types have been associated with an increased risk of certain diseases  
like arthr itis and other rheumatologic disorders, or a faster progression to AIDS. HLA 
typing will be performed on samples collected from all the enrolled subjects. Results 
from the HLA typing will become part of each subject’s medical record at the NIH. 
Medical rec ords containing this information are maintained in a secure place.  
9.2 Potential Benefits  
Improvement of HIV-specific immune control from the vaccine regimen is a potential 
benefit for subjects  randomized to the vaccine arm.   
10  Research Use of Stored Human Samples, Specimens or Data  
 Intended use: Stored blood s amples and data collected under this protocol may be 
used to study the effect of the HIV -MAG pDNA vaccine prime in combination with the 
IL-12 pDNA adjuvant and the rVSV HIV gag booster vaccine on  the v irologic and 
immunologic parameters listed in Section 8.2. Samples may also be used to study 
other aspects of the immunopathogenesis of HIV infection  or measure serum levels of 
antiretroviral agents during ATI .  
 Storage: Access to stored samples will be limited using a locked room or a locked 
freezer. Samples and data will be stored using codes assigned by the investigators. 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 51 of 72 Data will be kept in password -protected computers. Only investigators will have 
access to the samples and data.  
 Tracking: Samples  will be tracked utilizing the repository operated by SAIC 
Frederick, Inc. Data will be stored and maintained in the NIAID CRIMSON database.  
 Disposition at the completion of the protocol : At the completion of the protocol 
(termination), sampl es and data will either be destroyed, or after IRB approval, 
transferred to another existing protocol.   
 Report ing the loss or destruction of samples/specimens/data to the IRB:  
 Any loss or unanticipated destruction of the samples or data (for example, due to 
freezer malfunction) that meets the NIH Intramural protocol deviation  definition or 
results in a deviation  that compromises the scientific integrity of the data collected 
for the study will be reported to the NIAID IRB.   
 Additionally, subjects may decide at any point not to have their samples stored. In 
this case, the principal investigator will destroy all known remaining samples and 
report what was done to the subject and the IRB. This decision will affect the 
subject’ s participation in this protocol , but it may not affect participation in other 
protocols at the NIH.  
11 Remuneration Plan for Subjects  
Subjects will receive financial compensation for leukapheresis according to the NIH  
Clinical Cente r volunteer guidelines: $100 for a 2 -pass leukapheresis procedure or $200 
for a 4 -pass leukapheresis procedure.  
12 Assessment of Safety  
12.1 Documenting, Recording, and Reporting Adverse Events  
At designated visits with the subject, information regarding AEs will be elicited by 
appropriate questioning and examinations , and it will be:  
 Immediately documented in the electronic database  and medical record . 
 Reported as outlined below (e.g., IND spon sor, IRB, Food and Drug 
Administration  [FDA]). 
12.2 Definitions  
Adve rse event  
An AE is any untoward or unfavorable medical occurrence in a human subject, 
including any abnormal sign (e.g., abnormal physical exam or laboratory finding), 
symptom, or disease temporally associated with the subject’s participation in the 
resea rch, whether or not considered related to the research.  
 
Adverse reaction   
An adverse reaction (AR) is an AE  that is caused by an investigational agent (drug 
or biologic).  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 52 of 72  
Suspected adverse reaction  
A suspected AR (SAR) is a n AE for which there is a reasonable possibility that the 
investigational agent caused the AE. ‘Reasonable possibility’ means that there is 
evidence to suggest a causal relationship between the drug and the AE. A SAR 
implies a lesser degree of certainty about the causality than an AR,  which implies a 
high degree of certainty.  
 
Serious adverse event  
An SAE  is an AE that results in one or more of the following  outcomes:  
 Death.  
 A life -threatening (i.e., an immediate threat to life) event.  
 An inpatient hospitalization or prolongation of an existing hospitalization.  
 A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions . 
 A congenital anomaly/birth defect.  
 A medically important event .* 
*Medical and scientific judgment should be exercised in deciding whether 
expedited reporting is appropriate in other situations, such as important medical 
events that may not  be immediately life threatening or result in death or 
hospitalization , but they ma y jeopardize the subject or may require intervention to 
prevent one of the other outcomes listed above.  
 
Unexpected adverse event  
An AE is unexpected if it is not listed in  the investigator’s brochure  or package  
insert (for marketed pr oducts) , or it is not listed at the specificity or severity that has 
been observed. It is the responsibility of the IND spon sor to make this 
determination.  
 
Serious and unexpected suspected adverse reaction  
A serious and unexpected suspected AR ( SUSAR ) is a SAR that is both  serious 
and unexpected.   
 
Unanticipated problem  
An unanticipated problem (UP) is an event, incident, experience, or outcome that 
is—  
1. Unexpected in terms of nature, severity, or frequency in relation to — 
a. The research risks that are described in the IRB-approved research 
protocol and informed consent document; investigator’s brochure, or other 
study documents; and  
b. The characteristics of the subject population being studied; and  
2. Possibly, probably, or definitely related to participation in the research ; and  
3. Places subjects or others at a greater risk of harm (including physical, 
psychological , economic, or social harm) than was previously known or 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 53 of 72 recognized ( per the IND sponsor, an AE with a serious outcome will be 
considered increased risk) . 
 
Unantici pated problem that is not an adverse event  
An unanticipated problem that is not an AE is incident, experience , or outcome that 
is not associated with an AE, which meets the 3 criteria of a UP. Examples include 
breaches of confidentiality, accidental destr uction of study records, and  
unaccounted -for study drug.  
 
Protocol Deviation  
Any change, divergence, or departure from the IRB approved study procedures in 
a research protocol. Protocol deviations are designated as serious or non -serious 
and further characterized as : 
 
1. Those that occur because a member of the research team deviates from the 
protocol.  
2. Those that are identified before they occur, but cannot be prevented.  
3. Those that are discovered after they occur  
 
 
Serious Protocol Deviation:  A deviation that meets the definition of a Serious 
Adverse Event or compromises the safety, welfare or rights of subjects or others.  
 
 
Non-compliance: The failure to comply with applicable NIH HRPP policies, IRB 
requirements, or regulatory requirements fo r the protection of human subjects. 
Non-compliance is further characterized as : 
1. Serious: Non -compliance that  
a. Increases risks, or causes harm, to participants  
b. Decreases potential benefits to participants  
c. Compromises the integrity of the NIH -HRPP  
d. Invalidates  the study data  
2. Continuing: Non -compliance that is recurring  
3. Minor: Non -compliance that, is neither serious nor continuing.  
Protocol specified events  
Protocol specified events  are AEs specified in the protocol that the principal 
investigator , IND sponsor, or medical monitor would like to review in real time 
rather than weeks or months later , when they would otherwise appear in various 
line listings. These events may or may not also be SAEs.  
12.3 Investigator Assessment of Adverse Events  
If a diagnosis is clinically evident (or subsequently determined), the diagnosis 
rather than the individual signs and symptoms or lab abnormalities will be recorded 
as the AE.  
 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 54 of 72 All AEs occurring from the time when the first vaccine dose is administered through 
the specified  study follow -up period, recorded, and reported.  The principal 
investigator will evaluate all AEs with respect to Seriousness  (criteria listed 
above), Severity (intensity or grade), and Causality  (relationship to study agent 
and relationship to research) according to the following guidelines.  
12.3.1  Severity  
The principal i nvestigator will grade the severity of each AE according to the 
Division of Aids Table for Grading the Severity of Adult and Pediatric Adverse 
Events Version 1.0, December, 2004 , (Clarification  August 20) which can be 
found at:   
http://rsc.techres.com/Document/safetyandpharmacovigilance/Table_for_Gradin
g_Se verity_of_Adult_Pediatric_Adverse_Events.pdf   
  
Subjective reactogenicity symptoms (such as malaise, fatigue, injection sit e 
pain, headache, chills ) will not be given a grade 3 score unless they persist for 
>3 days.  
 
Some grade 1 lab parameters on the DAIDS toxicity table (fibrinogen, low 
calcium levels , high fasting glucose, low phosphate  levels , low potassium levels , 
low sodium levels , elevated uric acid levels [ males only ]) fall within the NIH l ab 
reference range fo r normal values.  These normal values will not be reported as 
grade 1 AEs. The grade 1 values for these tests will be reported as follows:  
 Fibrinogen: 100 –176 mg/dL . 
 Phosphate (low): There is no grade 1 reportable value .  
 Sodium (low): 130 –134 mmol/L . 
 Potas sium (low): 3.0 –3.2 mmol/L . 
 Calcium (low): 1.95 –2.04 mmol/L . 
 Glucose (high, fasting): 116 –125 mg/dL . 
 Uric Acid (males): 8.7 –10.0 mg/dL .  
12.3.2  Causality    
Causality (likelihood that the event is related to the study agent) will be  
assessed considering the factors listed under the following categories:  
 
Definitely related     
 Reasonable temporal relationship.  
 Follows a known response pattern.  
 Clear evidence to sugge st a causal relationship . 
 There is no alternative etiology.  
 
Probably  related   
 Reasonable temporal relationship.  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 55 of 72  Follows a suspected response pattern (based on similar agents).  
 No evidence of a more likely alternative etiology.  
 
Possibly related   
 Reasonable tem poral relationship . 
 Little evidence for a more likely alternativ e etiology.  
 
Unlikely related   
 Does not have a reasonable temporal relationship .  
OR 
 Good evidence for a more likely alternative etiology.  
 
Not related   
 Does not have a temporal relationship .          
OR 
 Definitely due to an alternative etiology . 
 
Note:    
Other factors (e.g., dechallenge, rechallenge) should also be considered for 
each causality category when appropriate. Causality assessment is based on 
available information at the time of the assessment of the AE. The investigator 
may revise the causalit y assessment as additional information becomes 
available.  
12.4 Investigator Reporting Responsibilities to the  Sponsor  
12.4.1  Adverse Events  
Line listings , frequency tables, and other summary AE data will be submitted to 
the IND sponsor per the Safety Review and Communications Plan (SRCP – see 
below), or as needed for periodic safety assessments, review of IND annual 
reports, review of IND safety reports, and preparation of final study reports.  
12.4.2  Serious Adverse Events  
SAEs (whether or not they are also UPs) must be reported on the SAE/UP report  
form and sent  to the sponsor Clinical Safety Office (CSO) by fax or e -mail 
attachment. Deaths and immediately life -threatening SAEs must be reported 
within 1 business day after the site becomes aware of the event. All other SAEs 
must be reported within 3 business days of site awareness.  
 
Sponsor clinical safety office contact information:  
OCRPRO  Clinical Safety Offic e 
5705 Industry Lane  
Frederick , MD 21704  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 56 of 72  
Phone 301 -846-5301  
Fax 301 -846-6224  
E-mail: rchspsafety@mail.nih.gov   
12.4.3  Unanticipated Problems  
Non-serious  AEs that are UPs must also be reported on the SAE/UP report f orm 
and sent  to the CSO by fax or e -mail attachment no later than 7 calendar days 
of site  awareness of the event. UPs that are not AEs are not reported to the 
spon sor CSO.  
12.4.4  Protocol Specified Events  
Autoimmune disorders are AEs of special interest. A sample list of autoimmune 
disorders is provided in Appendix C . These protocol specified events  must be 
reported to the CSO on a SAE/UP report form  within 3 business days of site the 
awareness.    
12.4.5  Pregnancy  
Pregnancy itself is not an AE. However, complications of pregnancies are AEs 
and may be SAEs. Pertinent obstetrical information for all pregnancies , including 
pregnancies disclosed by the subject as occurring in a partner of a male subject,  
will be reported to the CSO via fax or e -mail within 3 business days from the site 
awareness of the pregnancy.   
 
Pregnancy outcome data (e.g., delivery outcome, spontaneous or elective 
termination of the pregnancy) will be reported to the CSO within 3 business days 
of the site awareness on a protocol -specified form.  In the event of pregnancy, 
the following steps will be taken:  
 Discontinuation of the study agent s. 
 Unblind per the unblinding section of the protocol . 
 Withdraw from the study but co ntinue follow ing for safety . 
 Report to safety oversight committee ( Data and Safety  Monitoring Board 
[DSMB ]) and the IRB. 
 Advise research subject to notify the obstetrician of study agent exposure . 
12.5 Investigator Reporting Responsibilities to the NIAID IRB   
12.5.1  Expedited Reporting to the NIAID IRB   
Serious and non -serious Unanticipated Problems, deaths, serious deviations, 
and serious or continuing non -compliance will be reported within 7 calendar 
days of investigator awareness.  SAEs that are possibly, probably, or definitely 
related to the research will be reported to the NIAID IRB within 7 calendar 
days of investigator awareness, regardless of expectedness.  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 57 of 72 12.5.1.1.  Waiver of Reporting Anticipated Protocol Deviations, Expected 
UP nonAEs and Deaths to the NIAID IRB  
 
Anticipated deviations in the conduct of the protocol will not be reported 
to the IRB unless they occur at a rate greater than anticipated by the 
study team. Expected adverse events will not be reported to the IRB 
unless  they occur at a rate greater than that known to occur in HIV(+) 
population . If the rate of these events exceeds the rate expected by the 
study team, the events will be classified and reported as though they are 
unanticipated problems. Deaths related to th e natural history of HIV (+) 
population will be reported at the time of continuing review.  
12.5.2  Annual Reporting to the NIAID IRB   
The following items will be reported to the NIAID IRB in summary at the time of 
continuing review:  
 Serious and non -serious unantic ipated problems  
 Expected serious adverse events that are possibly, probably, or 
definitely related to the research  
 Serious adverse events that are not related to the research  
 All adverse events, except expected AEs and deaths granted a waiver 
of reporting .  
 Serious and Non -Serious Protocol deviations  
 Serious, continuing, and minor non -compliance  
 Any trends or events which in the opinion of the investigator should be 
reported  
12.6 Follow -up of  Adverse Events and Serious Adverse Events  
AEs that occur following e nrollment of subject s (i.e., after the first vaccination ) are 
followed until the final outcome is  known or until the end of the study follow -up 
period.  
 
SAEs that have not resolved by the end of the follow -up period are followed until the 
final outcome is known. If it is not possible to obtain a final outcome for an SAE 
(e.g., the subject is lost to follow  up), the reason a final outcome could not be 
obtained will be recorded by the investigator on the  SAE/UP report form .  
 
SAEs that occur afte r study completion ( month  24) that are reported to and are 
assessed by the investigator to be possibly, probably, or definitely related must be 
reported to the CSO, as described above.  
12.7 Sponsor’s Reporting Responsibilities  
SUSARs as defined in 21 Code of Federal Regulations (CFR) 312.32 and 
determined by the IND sponsor will be reported to the FDA and all participating 
investigators as IND safety reports.  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 58 of 72  
The IND sponsor will also submit an IND annual report of the progress of the 
investigation t o the FDA as defined in 21 CFR 312.33.  
12.8 Halting Criteria for the Protocol  
Halting the study requires immediate discontinuation of the study agents  
administered for all subjects and suspension of enrollment until a decision is made 
about whether or not to  continue study agent administration.   
  
The halting criteria (as determined by the study principal investigator  and IND 
sponsor secondary to  aggregate data review) for this study include:  
 Any SAE or grade  4 AE that is  possibly, probably, definitely related  to the study 
agent; OR  
 Any death; OR  
 Any safety issue that the study principal investigator  or IND sponsor 
determines should halt the study.  
 
Any related AE that is ≥ grade 3 (not including transient, subjective reactogenicity 
symptoms such as malaise, fatigue, injection site pain, he adache, chills ) will be 
review ed within 48 hours of site awareness, by the principal investigator and IND 
sponsor medical monitor , to consider the need for halting the protocol . 
 
The IRB, the IND sponsor, DSMB, or the FDA may halt the study at any time due 
to safety concerns.  
 
Halting is carried out by or through the principal investigator  (or designee if 
unavailable) within 24 hours of the decision to halt the trial, regardless o f the party 
initiating the halt, whether the halt is due to the criteria defined above or another 
issue.  
12.8.1  Reporting of Study Halting  
If the study is halted , a description of the event(s) or safety issue must be 
reported by the principal investigator  within 1 business day to the sponsor CSO 
and the NIAID IRB by fax or e -mail.  
12.8.2  Resumption of a Halted Study  
The IND spons or, in collaboration with the principal investigator  and the DSMB , 
will determine if it is safe to resume the study. The IND sponsor will notify the 
principal investigator of this decision. The conditions for resumption of the 
study will be defined in this notification. The principal investigator  will notify the  
IRB of the decision to resume the study.  
12.9 Pausing  Criteria  for a Subject or Group   
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 59 of 72 The decision to suspend administration of the study agent(s) for a single subject ,  
or for all the subjects in the study , requires discontinuation of the study agent 
administrated f or the study subject(s)  until a decision is made whether or not to 
continue study agent administration.   
 
The pausing criteria for a single subject or for all the subjects in this study include:  
 
 A subject  or 3 subjects experience an SAE or grade  3 or greater AE  (not 
including transient, subjective reactogenicity symptoms such as malaise, 
fatigue, injection site pain, headache, chills, or total bilirubin in subjects taking 
atazanavir )  that is unexpected (as determined by the IND spons or) and is 
possibly, probabl y, or definitely  related to the study agent;  
OR 
 2 subjects experience grade  4 local or sys temic reactogenicity symptom(s)  or 
AE that is considered to be related to the study vaccination.  
            OR 
 Any safety issue that the site investigator determines should pause 
administration of the study agent to a single subject or to all the subjects in the 
study.  
 The IND sponso r, in collaboration with the principal investigator , may also 
pause for an individual subject or the entire group if a safety concern is identified 
during routine aggregate data analysis.  
12.9.1  Reporting of Pausing for a Subject or Group  
If a pausing requirement is met, a description of the AE(s) or safety issue must 
be reported by the principal investigator  by fax or e -mail within 1 business day 
to the sponsor CSO, principal investigator , IRB, and the DSMB.    
12.9.2  Resumption of Paus ing for a Subject or Group  
The IND sponsor in collaboration with the principal investigator  and/or the 
relevant DSMB  will determine if it is safe to resume administration of the study 
agents to the subject/group. The IND sponsor will notify the principal 
investigator  of this decision. The principal investigator  will notify the IRB  of the 
decision to resume administration  of the study agent prior to resumption.  
12.10  Withdrawal Criteria for an Individual Subject  
An individual subject will be withdrawn for any of the following:  
 An individual subject’s decision.  
(The investigator will attempt to determine the reason for the subj ect’s decision ,  
and will strongly suggest a follow -up plan to help ensure the subject safely 
returns to baseline or better, if possible ). 
 Co-enrollment in a study with an investigational research agent (rare exception 
allowing the continuation  of the study vaccinations  granted by the principal 
investigator ).  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 60 of 72  2 consecutive viral loads >400 copies/m L while on cART  during the vaccination 
phase of the study.  
 Development of an AIDS defining opportunistic infection (OI). Any subject who 
develops an AIDS  OI will have repeat assessments of of CD4 counts weekly 
until counts rise to >200 cells/mm3 on at least 2 successive assessments” . 
 2 consecutive CD4 counts showing a  >30% decline from pre -vaccination 
baseline  or an absolute CD4 cell count <350 cells/mm3 while on cART  during 
the vaccination phase of the study.  
 Any SAE or grade 4 local or systemic reactogenicity symptom, lab abnormality, 
or AE that is subsequently considered to be related to the study vaccination(s).  
 Clinically significant type 1 hypersensitivity reaction associated with the study 
vaccination(s). In the event of a type 1 hypersensitivity reaction that is NOT 
considered to be clinically significant, (e.g. , brief, mild, and self limited skin 
reaction without other symptoms), the principal investigator , in consultation with 
the sponsor medical monitor , may consider possible additional vaccinations 
with appropriate precautions.  
 Any clinical AE, laboratory abnormality , or other medical condition or situation 
such that continued participa tion in the study would not be in the best interest 
of the subject. Subjects will be followed for the duration of the study for 
indicated safety assessments.  
 Non-compliance with study procedures to the extent that it is potentially harmful 
to the subject o r to the integrity of the study data.  
 Pregnancy . 
 Participant misses more than 1 study vaccination s. 
 
If possible, all subjects who discontinue the study treatment prematurely will be 
followed through week 56 for all the study evaluations . 
12.11  Replacement for Withdrawn Subjects  
Any subject who withdraws from the study, or who discontinues the study 
vaccination s, prematurely before the 28th day of the last study vaccination, and 
whose reasons for withdrawing from the study or discontinuing study vaccination 
administration are unrelated to any real or perceived effect of the study 
vaccination s or their administration, will be replaced.  
12.12  Safety Oversight  
12.12.1  Safety Review and Communications Plan  
An SRCP has been developed for the protocol. The SRCP is an internal 
communications document between the principal investigator and the IND 
sponsor CSO, which delineates the safety oversight responsibilities of the 
principal investigator , the CSO, and other s takeholders. The SRCP also 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 61 of 72 includes the overall plan for conducting periodic safety surveillance 
assessments.   
12.12.2  Sponsor Medical Monitor  
A medical monitor, representing the IND spon sor (OCRPRO ), has been 
appointed for the safety oversight in this clinical study. The sponsor medical 
monitor will be  responsible for performing safety assessments as outlined in the 
SRCP.  
12.12.3  Data and Safety Monitoring Board  
The NIAID intramural  DSMB will review the study prior to initiation and twice a 
year there after. The Board may convene additional reviews as necessary. The 
Board will review the study data to evaluate the safety, efficacy, study progress, 
and conduct of the study. All SAEs , all UPs, and all IND safety reports will be 
reported by the principal i nvestigator to the DSMB at the same time they are 
submitted to the IRB or IND sponsor. The principal investigator  will notify the 
DSMB of any cases of intentional or unintentional unblinding as soon as 
possible. The principal investigator  will notify the Board at the time when 
pausing or halting criteria are met and obtain a recommendation concerning 
continuation, modification, or termination of the study. The principal investigator  
will submit the written DSMB summary reports with recommendations to the 
IRB.  
13 Clinical Monitoring Structure  
13.1 Site Monitoring Plan   
As per International Conference on Harmonization (ICH) Good Clinical Practice 
(GCP ) 5.18 FDA 21 CFR 312.50 , if under IND , clinical protocols are required to be 
adequately monitored by the study sponsor . This study monitoring will be 
conducted according to the NIAID Intramural Clinical Monitoring Guidelines.  
Monitors under contract to the NIAID/ OCRPRO  will visit the clinical research site to 
monitor aspects of the study in accordance with the appropriate regulations and 
the approved protocol. The objectives of a monitoring visit will be: 1) to verify the 
existence of signed informed consent documents and documentation of the 
informed consent form process for each monitored subject; 2) to verify the prompt 
and accurate recording of all monitored data points, and prompt reporting of all 
SAEs; 3) to compare abstracted information CRIMSON data abstracts  with 
individual subjects’ re cords and source documents (subjects’ charts, laboratory 
analyses and test results, physicians’ progress notes, nurses’ notes, and any other 
relevant original subject information); and 4) to help ensure that investigators are in 
compliance with the protoco l. The monitors also will inspect the clinical site 
regulatory files to ensure that regulatory requirements (Office for Human Research 
Protections  [OHRP ]), FDA,  and applicable guidelines (ICH -GCP) are being 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 62 of 72 followed. During the monitoring visits, the inves tigator (and/or designee) and other 
study personnel will be available to discuss the study progress and monitoring visit.  
 
The investigator (and/or designee) will make the study documents (e.g., consent 
forms, CRIMSON data abstracts , and pertinent hospital  or clinical records readily 
available for inspection by the local IRB, the FDA, the site monitors, and the NIAID 
staff for confirmation of the study data.  
 
A specific protocol monitoring plan will be discussed with the  principal investigat or 
and s tudy staff prior to enrollment. The plan will outline the frequency of the 
monitoring visits based on factors such as the study enrollment, data collection 
status , and regulatory obligations.   
13.1.1  Study Blinding and  Unblinding  
Study participants  and site staff (except for the NIH pharmacists) will be blinded 
to the participant treatment arm assignments (e .g., active vaccine or control). 
Any discussion about the study product assignment between the pharmacy staff 
and any other protocol  staff is pro hibited. The DSMB  members also are 
unblinded to the treatment assignment for the  review of trial safety.  
When a participant leaves the trial prior to study completion, the participant will 
be told he or she must wait until the all the participants are unb linded to learn 
about his or her treatment assignment.  
Emergency unblinding decisions will be made by the principal investigator. if 
time permits, the sponsor medical monitor will be consulted before emergency 
unblinding occurs.  
14 Compliance With NIH Guidelines for Research Involving Products Containing 
Recombinant  DNA  
Because this study is evaluating products containing recombinant DNA, it must comply 
with regulations set forth in the NIH’s Guidelines for Research Involving Recombinant 
DNA Molecules . Information about the study must be submitted to site Institutional 
Biosafety Committees and must be approved before participants are enrolled in the 
study. IBC review and approval must be documented by the investigator and submitted 
as part of protocol re gistration for this trial.  
The NIH guidelines also require that human gene transfer trials conducted at or 
sponsored by institutions that receive NIH funds must be submitted to the NIH Office of 
Biotechnology Activities for review by the Recombinant DNA Ad visory Committee.  
The study team and DAIDS will ensure that reporting requirements to the Recombinant 
DNA Advisory Committee, as outlined in Appendix M -I-C-1.Initiation of the Clinical  
Investigation , Appendix M -I-C-3.Annual Reports , and Appendix M -I-C-4.Safety Reporting 
are satisfied per the NIH guidelines.  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 63 of 72 15 Statistical Considerations  
15.1 Study Hypotheses  
The study will test the hypothesis that t herapeutic vaccination with the HIV-MAG 
pDNA vaccine prime in combination with the IL-12 pDNA adjuvant and the rVSV 
HIV gag booster will have acceptable safety  and tolerability  in a population of 
virally suppressed HIV -infected subjects who began cART during acute or early 
infection. The study will also test the hypothesis that HIV -specific immune 
responses induced by this vaccination strategy will have clinically significant 
antiviral activity in the absence of cART.  
15.2 Sample Size Justification   
The primary outcome  for this study is the occurrence  of SAEs or  grade 3 or higher 
AEs. The probability of at least 1 such event among 15 vaccine recipients is 1-(1-
P),15 where P is the probability that a given person has the event. Table 3 shows, 
for different values of P, the probability of observing at least 1 vaccine participant 
with an AE of probability P. For instance, P=.05 corresponds to an AE that occurs 
in about 5% of participants; the probability of this AE being observed for at l east 1 
of the 15 vaccine recipients is approximately 54%. This means that we cannot be 
confident of observing relatively rare events with a probability of 5% or less. On the 
other hand, the probability of observing at least 1 vaccine participant with an AE  of 
probability 15% is approximately 91%. This means that if we do not observe 
anyone with a given type of AE, we can be relatively confident that it occurs in 
fewer than 15% of the population.  
 
Table 3: Probability of observing at least 1 vaccine recipient out of 15 with an 
AE that has probability P of occurring in a given participant  
P =.05 P =.10 P =.15 P =.20 P=.25 
54% 79% 91% 96% 99% 
 
The p ower for a comparison of the 2 arms with respect to a given AE is low unless 
the event probability is high in the vaccine arm and very low in the placebo arm. For 
example, if the AE probabilities in the 2 arms are .55 and .05, then power using 
Fisher’s exact test is approximately 82%.  
 
To compute the power for the secondary outcome  of difference in plasma viremia at  
the end of the ATI phase of the study , we needed to estimate the standard deviation 
of rebound plasma viremia  in log 10 units. We used data from Rosenberg et al38 and 
Grijsen et al .45 The Rosenberg study had a similar design to the one being 
contemplated here, namely randomization to vaccine or placebo among acutely 
infected participants followed by ART interruption and d etermination of viral levels  
17-23 weeks following interruption. Rosenberg et al do not give the  standard 
deviation, but back calculation of this quantity from the confidence interval given 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 64 of 72 suggests a standard deviation between  0.64 and 0.90. The Grijsen study had an 
estimated standard deviation of close to 1 in the ART treatment arms, though their 
measure of rebound plasma viremia was determined following a longer period of 
time (36 weeks) f rom the treatment interruption. To be  conservative, we decided to 
adopt the larger standard deviation of 1. Although the Wilcoxon rank sum test will 
be used to compare the 2 groups with respect to viremia, power for the Wilcoxon 
test is very close to that of the t -test (the asymptotic relativ e efficiency is 
approximately 95%). Therefore, we approximated power for the Wilcoxon test by 
that of the t -test. The p ower based on a 2-sample t -test with a 2-tailed alpha of .05 
and a total sample size of 30 is approximately 91% to detect a 1.25 log 10 reduction 
in the rebound plasma viremia .   
16 Ethics/Protection of Human Subjects  
16.1 Informed Consent Process  
Informed consent is a process where information is presented to enable persons to 
decide voluntarily whether or not to participate as a research subject. It is an on -
going conversation between the human research subject and the researchers , 
which begins before consent is given and continues until the end of the subject's 
involvement in the research. Discussions about the research will provide essential 
information about the study and include: purpose, duration, experimental 
procedures, alternatives, risks , and benefits. Subjects will be given the opportunity 
to ask questions and have the  questions  answered.  
 
The subject s will sign the informed consent document prior to undergoing any 
research  procedures. The subject s may withdraw consent at any time throughout 
the course of the trial. A copy of the informed consent document will be given to 
the subject s for their records . The researcher will document the process of signing 
the consent form in the subject’s medical record. The rights and welfare of the 
subject s will be protected by emphasizing to them that the quality of their medical 
care will not be adversely affected if  they decline to participate in this study.  
16.2 Subject  Confidentiality  
All records will be kept confidential to the extent provided by federal, state , and 
local law. The study monitors and other authorized representatives of the sponsor 
may inspect all documents and records required to be maintained by the 
investigator , including , but not limited to, medical records. Records will be kept 
locked and all computer entry and networking programs will be done with coded 
numbers only . Clinical information will not be released without written permission of 
the subject, except as necessary for monitoring by the IRB, FDA, NIAID, OHRP, 
pharmaceutical supporter(s), or the sponsor’s designee.  
17 Data Handling and Record Keeping  
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 65 of 72 17.1 Data Management  Responsibilities  
The investigator is responsible for assuring that the data collected are complete , 
accurate, and recorded in a timely manner. Source documentation (the point of 
initial recording of information) should support the data collected in the el ectronic 
data system  and must be signed and dated by the person record ing and/or 
reviewing the data.  
17.2 Data Capture Methods  
Study data will be collected at the study site and maintained on  an electronic data 
system (CRIMSON). These forms or systems are to be completed on an ongoing 
basis during the study . Data entered into electronic data systems  shall be 
performed by authorized individuals. Corrections to electronic  data systems  shall 
be tracked electronically (password protected or through an audit trail)  with the 
time, date, individual making the correction, and what was changed.   
17.3 Types of Data  
Source documents include, but are not limited to, subjects ’ medical records, 
laboratory reports, ECG tracings,  x-rays, radiologist’s reports , biopsy reports, 
ultrasound photographs, progress notes, pharmacy records, and any other similar 
reports or records of procedures performed during the subjects ’ participation in the 
study.  
17.4  Source Documents  and Access to Source Data/Documents  
Source documents include all recordings of observations or notations of clinical 
activities, and all reports and records necessary for the evaluation and 
reconstruction of the clinical trial. Data from  the CRIMSON Data System  will be 
collected directly from subjects during study visits and telephone calls, or will be 
abstracted from subjects’ diaries/mem ory cards and medical records. Each  
subject’s medical record must record his/her participation in the clinical trial and,  
after unblinding , study treatment/vaccination (with doses and frequency) or other 
medical interventions or treatments administered, as well as any AEs experienced 
during the trial.  
17.5 Record Retention  
The investigator is responsible for retaining all the essential documents listed in the 
ICH G CP guideline s. All ess ential documentation for all the study subjects are to 
be maintained by the investigators in a secure storage facility for a minimum of 3 
years per NIAID policies.  The FDA requires study records to be retained for up to 2 
years after marketing approval or disapproval (21 CFR 312.62), or until at least 2 
years have elapsed since the formal discontinuation of clinical development of the 
investigational agent s for a specific indication.  These records are also to be 
maintained in compliance with IRB, state, and  federal medical records -retention 
HIV-MAG pDNA vaccine  version 6.0 
August 14, 2015  
Page 66 of 72 requirements, whichever is longest. All stored records are to be kept confidential to 
the extent required by federal, state, and local law.  
 
 
HIV-MAG  pDNA vaccine  version 6.0 
August 14,  2015 
 Appendix A: Scientific References  
 
1. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. 
Lancet 2010;376:49 -62. 
2. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The 
challenge of finding a cure for HIV infection. Science 2009;323:1304 -7. 
3. Trono D, Van Lint C, Rou zioux C, et al. HIV persistence and the prospect of long -term 
drug-free remissions for HIV -infected individuals. Science 2010;329:174 -80. 
4. Chun TW, Fauci AS. HIV reservoirs: pathogenesis and obstacles to viral eradication and 
cure. AIDS 2012;26:1261 -8. 
5. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV -1 latent reservoir 
during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997;94:13193 -7. 
6. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV -1 in patients 
on highly active antiretroviral therapy. Science 1997;278:1295 -300. 
7. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication -competent HIV 
despite prolonged suppression of plasma viremia. Science 1997;278:1291 -5. 
8. Chun TW, Nickle  DC, Justement JS, et al. HIV -infected individuals receiving effective 
antiviral therapy for extended periods of time continually replenish their viral reservoir. J 
Clin Invest 2005;115:3250 -5. 
9. Buzon MJ, Massanella M, Llibre JM, et al. HIV -1 replication  and immune dynamics are 
affected by raltegravir intensification of HAART -suppressed subjects. Nat Med 
2010;16:460 -5. 
10. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir -containing intensification on 
HIV burden and T -cell activation in multiple gut sites of HIV -positive adults on 
suppressive antiretroviral therapy. AIDS 2010;24:2451 -60. 
11. Davey RT, Jr., Bhat N, Yoder C, et al. HIV -1 and T cell dynamics after interruption of 
highly active antiretroviral therapy (HAART) in patients with a history of sustained viral 
suppression. Proc Natl Acad Sci U S A 1999;96:15109 -14. 
12. Chun TW, Davey RT, Jr., Engel D, Lane HC, Fauci AS. Re -emergence of HIV after 
stopping therapy. Nature 1999;401:874 -5. 
13. Deeks SG, Autran B, Berkhout B, et al. Towar ds an HIV cure: a global scientific strategy. 
Nat Rev Immunol 2012;12:607 -14. 
14. Chun TW, Engel D, Mizell SB, et al. Effect of interleukin -2 on the pool of latently 
infected, resting CD4+ T cells in HIV -1-infected patients receiving highly active anti -
retroviral therapy. Nat Med 1999;5:651 -5. 
15. Prins JM, Jurriaans S, van Praag RM, et al. Immuno -activation with anti -CD3 and 
recombinant human IL -2 in HIV -1-infected patients on potent antiretroviral therapy. AIDS 
1999;13:2405 -10. 
16. Lehrman G, Hogue IB, Pa lmer S, et al. Depletion of latent HIV -1 infection in vivo: a 
proof -of-concept study. Lancet 2005;366:549 -55. 
17. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV -1 in patients 
receiving valproic acid. The Journal of infec tious diseases 2007;195:833 -6. 
18. Archin NM, Eron JJ, Palmer S, et al. Valproic acid without intensified antiviral therapy 
has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS 
2008;22:1131 -5. 
19. Lalezari J, Mitsuyasu R, Deeks S, e t al. Successful and persistent engraftment of ZFN -
M-R5-D autologous CD4 T cells (SB -728-T) in aviremic HIV -infected subjects on 
HAART. 18th Conference on Retroviruses and Opportunistic Infections 2011;Boston, 
MA. 
20. Tebas P, Levine B, Binder G, et al. Di sruption of CCR5 in zinc finger nuclease -treated 
CD4 T cells: phase I trials. 18th Conference on Retroviruses and Opportunistic 
Infections 2011;Boston, MA.  
                                                                                           HIV-MAG pDNA vaccine  version 6.0 
           August  14, 2015 
 
Page 68 of 72 21. Hutter G, Nowak D, Mossner M, et al. Long -term control of HIV by CCR5 
Delta32/Delta32 stem -cell transplantation. N Engl J Med 2009;360:692 -8. 
22. Fuller DH, Rajakumar P, Che JW, et al. Therapeutic DNA vaccine induces broad T cell 
responses in the gut and sustained protection from viral rebound and AIDS in SIV -
infected rhesus macaques. PLoS One 2012;7 :e33715 . 
23. Schooley RT, Spritzler J, Wang H, et al. AIDS clinical trials group 5197: a placebo -
controlled trial of immunization of HIV -1-infected persons with a replication -deficient 
adenovirus type 5 vaccine expressing the HIV -1 core protein. The Journa l of infectious 
diseases 2010;202:705 -16. 
24. Garcia F, Climent N, Guardo AC, et al. A Dendritic Cell -Based Vaccine Elicits T Cell 
Responses Associated with Control of HIV -1 Replication. Science translational medicine 
2013;5:166ra2.  
25. Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nature 
biotechnology 1998;16:867 -70. 
26. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the 
immunogenicity of an HIV -1 DNA vaccine candidate in healthy volunteers. PLoS One 
2011;6:e19252.  
27. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance 
immune responses. Immunologic research 2008;42:219 -32. 
28. Luxembourg A, Evans CF, Hannaman D. Electroporation -based DNA immunisation: 
translation to the cli nic. Expert opinion on biological therapy 2007;7:1647 -64. 
29. Johnson JE, Coleman JW, Kalyan NK, et al. In vivo biodistribution of a highly attenuated 
recombinant vesicular stomatitis virus expressing HIV -1 Gag following intramuscular, 
intranasal, or intra venous inoculation. Vaccine 2009;27:2930 -9. 
30. Luckay A, Sidhu MK, Kjeken R, et al. Effect of plasmid DNA vaccine design and in vivo 
electroporation on the resulting vaccine -specific immune responses in rhesus 
macaques. Journal of virology 2007;81:5257 -69. 
31. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated 
vesicular stomatitis virus recombinants. Cell 2001;106:539 -49. 
32. Faguet GB. The effect of killed influenza virus vaccine on the kinetics of normal human 
lymphocyt es. The Journal of infectious diseases 1981;143:252 -8. 
33. Chun TW, Justement JS, Moir S, et al. Decay of the HIV Reservoir in Patients Receiving 
Antiretroviral Therapy for Extended Periods: Implications for Eradication of Virus. The 
Journal of infectious diseases 2007;195:1762 -4. 
34. Hecht FM, Wang L, Collier A, et al. A multicenter observational study of the potential 
benefits of initiating combination antiretroviral therapy during acute HIV infection. The 
Journal of infectious diseases 2006;194:725 -33. 
35. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for 
acute HIV -1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. 
Proc Natl Acad Sci U S A 2000;97:3382 -7. 
36. Zhang L, Ramratnam B, Tenner -Racz K, et al. Quantifying residual HIV -1 replication in 
patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605 -13. 
37. Jacobson JM, Pat Bucy R, Spritzler J, et al. Evidence that intermittent structured 
treatment interruption, but not im munization with ALVAC -HIV vCP1452, promotes host 
control of HIV replication: the results of AIDS Clinical Trials Group 5068. The Journal of 
infectious diseases 2006;194:623 -32. 
38. Rosenberg ES, Graham BS, Chan ES, et al. Safety and immunogenicity of thera peutic 
DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV -
1 infection. PLoS One 2010;5:e10555.  
39. Routy JP, Boulassel MR, Nicolette CA, Jacobson JM. Assessing risk of a short -term 
antiretroviral therapy discontinuati on as a read -out of viral control in immune -based 
therapy. J Med Virol 2012;84:885 -9. 
                                                                                           HIV-MAG pDNA vaccine  version 6.0 
           August  14, 2015 
 
Page 69 of 72 40. Scofield RH, Harley JB. Autoantigenicity of Ro/SSA antigen is related to a nucleocapsid 
protein of vesicular stomatitis virus. Proc Natl Acad Sci U S A 1991;88:3343 -7. 
41. Huang SC, Pan Z, Kurien BT, James JA, Harley JB, Scofield RH. Immunization with 
vesicular stomatitis virus nucleocapsid protein induces autoantibodies to the 60 kD Ro 
ribonucleoprotein particle. Journal of investigative medicine : the official public ation of 
the American Federation for Clinical Research 1995;43:151 -8. 
42. Hardgrave KL, Neas BR, Scofield RH, Harley JB. Antibodies to vesicular stomatitis virus 
proteins in patients with systemic lupus erythematosus and in normal subjects. Arthritis 
and r heumatism 1993;36:962 -70. 
43. Routsias JG, Sakarellos -Daitsiotis M, Detsikas E, Tzioufas AG, Sakarellos C, 
Moutsopoulos HM. Antibodies to EYRKK vesicular stomatitis virus -related peptide 
account only for a minority of anti -Ro60kD antibodies. Clinical and e xperimental 
immunology 1994;98:414 -8. 
44. Symmons DP. Review of UK data on the rheumatic diseases --8. SLE. British journal of 
rheumatology 1991;30:288 -90. 
45. Grijsen ML, Steingrover R, Wit FW, et al. No treatment versus 24 or 60 weeks of 
antiretroviral tr eatment during primary HIV infection: the randomized Primo -SHM trial. 
PLoS Med 2012;9:e1001196 . 
 
  
                                                                                        HIV-MAG pDNA vaccine  version 6.0  
August 14, 2015 
 
Page 70 of 72 Appendix B: Schedule of Evaluations  
 
See attached  document .  
 
HIV-MAG pDNA vaccine  version 6.0 
August  14, 2015 
 Appendix C: AEs of  Special Interest  
 
AEs of special interest for this protocol include, but are not limited to, autoimmune disorders;  
representative examples of AES of special interest are listed below.  
Neuroinflammatory disorders   
Optic neuritis  Myasthenia gravis  
Multiple sclerosis  Encephalitis  
Demyelinating disease  Neuritis  
Transverse myelitis  Bell’s palsy  
Guillain -Barré syndrome   
 
Musculoskeletal disorders   
Systemic lupus erythematosus  Juvenile rheumatoid arthritis  
Cutaneous lupus  Polymyalgia rheumatic  
Sjogren’s syndrome  Reactive arthritis  
Scleroderma, dermatomyositis  Psoriatic arthropathy  
Polymyositis  Ankylosing spondylitis  
Rheumatoid arthritis  Spondyloarthropathy  
 
Gastrointestinal disorders   
Crohn’s disease  Celiac disease  
Ulcerative colitis   
 
Metabolic diseases   
Autoimmune thyroiditis  Insulin -dependent diabetes mellitus  
Grave’s or Basedow’s disease  Addison’s disease  
Hashimoto thyroiditis  Insulin -dependent diabetes mellitus  
 
Skin disorders   
Psoriasis  Erythema nodosum  
Vitiligo  Autoimmune bullous skin diseases  
Raynaud’s phenomenon   
Others   
Autoimmune hemolytic anemia  Primary sclerosing cholangitis  
Idiopathic thrombocytopenic purpura  Autoimmune glomerulonephritis  
Antiphospholipid syndrome  Autoimmune uveitis  
Temporal arteritis  Autoimmune cardiomyopathy  
Behcet’s syndrome  Sarcoidosis  
Pernicious anemia  Stevens -Johnson syndrome  
Autoimmune hepatitis  Vasculitides  
Primary biliary cirrhosis   
 
  
                                                                                        HIV-MAG pDNA vaccine  version 6.0  
August 14, 2015 
 
Page 72 of 72 Appendix D: Vaccine Diary Card  
 
See attached  document .  